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Preamble
A primary challenge in the development of clinical prac-
tice guidelines is keeping pace with the stream of new data
upon which recommendations are based. In an effort to
respond more quickly to new evidence, the American
College of Cardiology/American Heart Association (ACC/
AHA) Task Force on Practice Guidelines has created a new
“focused update” process to revise the existing guideline
recommendations that are affected by evolving data or
opinion. Before the initiation of this focused approach,
periodic updates and revisions of existing guidelines re-
quired up to 3 years to complete. Now, however, new
evidence will be reviewed in an ongoing fashion to more
efficiently respond to important science and treatment
trends that could have a major impact on patient outcomes
and quality of care. Evidence will be reviewed at least
twice a year, and updates will be initiated on an as needed
basis as quickly as possible while maintaining the rigorous
methodology that the ACC and AHA have developed
during their more than 20 years of partnership.
These updated guideline recommendations reflect a con-
sensus of expert opinion following a thorough review primar-
ily of late-breaking clinical trials identified through a broad-
based vetting process as important to the relevant patient
population and of other new data deemed to have an impact
on patient care (see Section 1.1 for details regarding this
focused update). It is important to note that this focusedupdate is not intended to represent an update based on a full
literature review from the date of the previous guideline
publication. Specific criteria/considerations for inclusion of
new data include:
• Publication in a peer-reviewed journal
• Large, randomized, placebo-controlled trial(s)
• Nonrandomized data deemed important on the basis of
results that impact current safety and efficacy assumptions
• Strengths/weakness of research methodology and findings
• Likelihood of additional studies influencing current find-
ings
• Impact on current performance measure(s) and/or likeli-
hood of the need to develop new performance measure(s)
• Requests and requirements for review and update from the
practice community, key stakeholders, regulatory agen-
cies, and other sources free of relationships with industry
or other potential bias
• Number of previous trials showing consistent results
• Need for consistency with other new guidelines or guide-
line revisions
In analyzing the data and developing updated recommendations
and supporting text, the focused update writing group used
evidence-based methodologies developed by the ACC/AHA Task
Force on Practice Guidelines, which are described elsewhere.1,2
The schema for class of recommendation and level of
evidence is summarized in Table 1, which also illustrates
how the grading system provides estimates of the size of
the treatment effect and the certainty of the treatment
effect. Note that a recommendation with Level of Evidence
B or C does not imply that the recommendation is weak.
Many important clinical questions addressed in guidelines
do not lend themselves to clinical trials. Although random-
ized trials may not be available, there may be a very clear
clinical consensus that a particular test or therapy is useful
and effective. Both the class of recommendation and level
of evidence listed in the focused updates are based on
consideration of the evidence reviewed in previous itera-
tions of the guidelines as well as the focused update. Of
note, the implications of older studies that have informed
recommendations but have not been repeated in contem-
porary settings are carefully considered.
The ACC/AHA practice guidelines address patient popu-
lations (and health care providers) residing in North America.
As such, drugs that are not currently available in North
America are discussed in the text without a specific class of
recommendation. For studies performed in large numbers of
subjects outside of North America, each writing committee
reviews the potential impact of different practice patterns and
patient populations on the treatment effect and on the rele-
vance to the ACC/AHA target population to determine
whether the findings should form the basis of a specific
recommendation.
The ACC/AHA practice guidelines are intended to assist
health care providers in clinical decision making by
describing a range of generally acceptable approaches for
the diagnosis, management, and prevention of specific
diseases or conditions. The guidelines attempt to define
practices that meet the needs of most patients in most
he indiv
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circumstances. The ultimate judgment regarding care of a
particular patient must be made by the health care provider
and patient in light of all the circumstances presented by
that patient. Thus, there are circumstances in which devi-
ations from these guidelines may be appropriate. Clinical
decision making should consider the quality and availabil-
ity of expertise in the area where care is provided. These
guidelines may be used as the basis for regulatory or payer
decisions, but the ultimate goal is quality of care and
serving the patient’s best interests.
Prescribed courses of treatment in accordance with these
recommendations are only effective if they are followed by
the patient. Because lack of patient adherence may adversely
affect treatment outcomes, health care providers should make
every effort to engage the patient in active participation with
Table 1. Applying Classification of Recommendations and Level
Data available from clinical trials or registries about the usefulness/efficac
myocardial infarction, history of heart failure, and prior aspirin use. A recommen
Many important clinical questions addressed in the guidelines do not lend the
be a very clear clinical consensus that a particular test or therapy is useful o
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed
recommendations have been written in full sentences that express a complet
the rest of the document (including headings above sets of recommendations
increase readers’ comprehension of the guidelines and will allow queries at tprescribed treatment.The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived
conflict of interest arising from industry relationships or
personal interests of a writing committee member. All writing
committee members and peer reviewers were required to
provide disclosure statements of all such relationships per-
taining to the trials and other evidence under consideration
(see Appendixes 1 and 2). Final recommendations were
balloted to all writing committee members. Writing commit-
tee members with significant (greater than $10 000) relevant
relationships with industry (RWI) were required to recuse
themselves from voting on that recommendation. Writing
committee members who did not participate are not listed as
authors of this focused update.
With the exception of the recommendations presented in
ence†
rent subpopulations, such as gender, age, history of diabetes, history of prior
ith Level of Evidence B or C does not imply that the recommendation is weak.
to clinical trials. Even though randomized trials are not available, there may
ve.
suggested phrases to use when writing recommendations. All guideline
ht, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
idual recommendation level.of Evid
y in diffe
dation w
mselves
r effecti
a list of
e thoug
), wouldthis statement, the full guidelines remain current. Only the
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 recommendations from the affected section(s) of the full
guidelines are included in this focused update. For easy
reference, all recommendations from any section of guide-
lines impacted by a change are presented with a notation as
to whether they remain current, are new, or have been
modified. When evidence impacts recommendations in
more than 1 set of guidelines, those guidelines are updated
concurrently.
The recommendations in this focused update will be
considered current until they are superseded by another
focused update or the full-text guidelines are revised. This
focused update is published in the January 15, 2008, issue of
the Journal of the American College of Cardiology, the
January 15, 2008, issue of Circulation, and e-published in
Catheterization and Cardiovascular Interventions as an up-
date to the full-text guidelines and is posted on the ACC
(www.acc.org), AHA (my.americanheart.org), and Society
for Angiography and Interventions (SCAI) (www.scai.org)
Web sites. Copies of the focused update are available from all
organizations.
Sidney C. Smith, Jr., MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
Vice-Chair, ACC/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Evidence Review
Selected late-breaking clinical trials presented at the 2005 and
2006 annual scientific meetings of the ACC, AHA, and
European Society of Cardiology, as well as selected other
data, were reviewed by the standing guideline writing com-
mittee along with the parent Task Force and other experts to
identify those trials and other key data that might impact
guideline recommendations. On the basis of the criteria/
considerations noted above, recent trial data and other clinical
information were considered important enough to prompt a
focused update of the ACC/AHA/SCAI 2005 Guideline
Update for Percutaneous Coronary Intervention.3–13
To provide clinicians with a comprehensive set of data,
whenever possible, the exact event rates in various treatment
arms of clinical trials are presented to permit calculation of
the absolute risk difference (ARD) and number needed to
treat (NNT) or harm (NNH); the relative treatment effects are
described either as odds ratio (OR), relative risk (RR), or
hazard ratio (HR), depending on the format in the original
publication.
Consult the full-text version or executive summary of the
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous
Coronary Intervention for policy on clinical areas not covered
by the focused update.13a Individual recommendations up-
dated in this focused update will be incorporated into future
revisions and/or updates of the full-text guidelines.
1.2. Organization of Committee and
Relationships With Industry
For this focused update, all members of the 2005 PCI writing
committee were invited to participate; those who agreed
(referred to as the 2007 focused update writing group) wererequired to disclose all RWI relevant to the data under
consideration.2 Focused update writing group members who
had no significant relevant RWI wrote the first draft of the
focused update; the draft was then reviewed and revised by
the full writing group. Each recommendation required a
confidential vote by the writing group members before
external review of the document. Any writing committee
member with a significant (greater than $10 000) RWI
relevant to the recommendation was recused from voting on
that recommendation.
1.3. Review and Approval
This document was reviewed by 2 outside reviewers nomi-
nated by each cosponsoring organization (ACC, AHA, and
SCAI) and 24 individual content reviewers. All reviewer
RWI information was collected and distributed to the writing
committee and is published in this document (see Appendix 2
for details).
This document was approved for publication by the gov-
erning bodies of the American College of Cardiology Foun-
dation, AHA, and SCAI.
2. Patients With Unstable Angina/Non–ST-
Elevation Myocardial Infarction
This 2007 PCI Focused Update section regarding patients
with unstable angina (UA)/non–ST-elevation myocardial
infarction (NSTEMI) is based on recommendations from
the ACC/AHA 2007 Guidelines for the Management of
Patients With Unstable Angina/Non–ST-Elevation Myo-
cardial Infarction,14 which emphasize the importance of
assessing risk of cardiovascular events as a guide to
therapeutic decision making and the need for interven-
tional therapy (see Table 2).
Because of the importance of several new changes in the
ACC/AHA 2007 UA/NSTEMI Guidelines, selected text from
the guidelines is included in the following paragraphs and
summarized in Table 2.
A number of risk-assessment tools have been developed to
assist in assessing risk of death and ischemic events in
patients with UA/NSTEMI, thereby providing a basis for
therapeutic decision making. It should be recognized that the
predictive ability of these commonly used risk assessment
scores for risk of nonfatal coronary heart disease (CHD) is
only moderate.
The Thrombolysis in Myocardial Infarction (TIMI) risk
score15 is a simple tool composed of 7 (1-point) risk indica-
tors rated on presentation (Table 4). The composite end points
(all-cause mortality, new or recurrent myocardial infarction
[MI], or severe recurrent ischemia prompting urgent revas-
cularization within 14 days) increase as the TIMI risk score
increases. The TIMI risk score has been validated internally
within the TIMI IIB trial and 2 separate cohorts of patients
from the ESSENCE (Efficacy and Safety of Subcutaneous
Enoxaparin in Unstable Angina and Non–Q-Wave Myocar-
dial Infarction) trial.16 The model remained a significant
predictor of events and appeared relatively insensitive to
missing information, such as knowledge of previously docu-
mented coronary stenosis of 50% or greater. The model’s
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 predictive ability remained intact, with a cutoff of 65 years of
age. The TIMI risk score was recently studied in an un-
selected emergency department population with chest pain
syndrome; its performance was similar to that in the acute
coronary syndrome (ACS) population from which it was
derived and validated.17 The TIMI risk calculator is available
at www.timi.org. The TIMI risk index, a modification of the
TIMI risk score that uses the variables age, systolic blood
pressure, and heart rate, has not only been shown to predict
short-term mortality in ST-elevation myocardial infarction
(STEMI) but also has been useful in prediction of 30-day and
1-year mortality rates across the spectrum of patients with
ACS, including UA/NSTEMI.18
The PURSUIT (Platelet Glycoprotein IIb-IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy) trial
risk model,19 based on patients enrolled in the PURSUIT
trial, is another useful tool to guide the clinical decision-
making process when the patient is admitted to the hospital.
In the PURSUIT risk model, critical clinical features associ-
ated with an increased 30-day incidence of death and the
composite of death or myocardial (re)infarction were (in
order of strength) age, heart rate, systolic blood pressure,
Table 2. Updates to Section 5.3: Initial Conservative Versus Initi
2005 PCI Guideline Update Recommendation 2007
An early invasive PCI strategy is indicated for patients with UA/
NSTEMI who have no serious comorbidity† and coronary lesions
amenable to PCI. Patients must have any of the following high-
risk features:
a. Recurrent ischemia despite intensive anti-ischemic therapy.
(Level of Evidence: A)
b. Elevated troponin level. (Level of Evidence: A)
c. New ST-segment depression. (Level of Evidence: A)
d. HF symptoms or new or worsening MR. (Level of Evidence:
A)
e. Depressed LV systolic function. (Level of Evidence: A)
f. Hemodynamic instability. (Level of Evidence: A)
g. Sustained ventricular tachycardia. (Level of Evidence: A)
h. PCI within 6 months. (Level of Evidence: A)
i. Prior CABG. (Level of Evidence: A)
j. High risk score (e.g., TIMI, GRACE). (Level of Evidence: A)
k. High risk findings from non-invasive testing. (Level of
Evidence: A)
1. An early invas
UA/NSTEMI wh
coronary lesio
characteristics
3.3 of the ACC
Evidence: A)
2. Percutaneous
for UA/NSTEM
without signifi
with a large a
on noninvasive
3. Percutaneous
for UA/NSTEM
suitable coron
without diabet
4. An intravenous
NSTEMI patien
Section 3.2.3
NSTEMI Guide
5. An early invas
intent to perfo
patients who h
electrical insta
contraindicatioST-segment depression, signs of heart failure (HF), and
cardiac enzymes.19
The GRACE (Global Registry of Acute Coronary
Events) study risk model, which predicts in-hospital mor-
tality (and death or MI), can be useful to clinicians to guide
treatment type and intensity.20,21 The GRACE risk tool
was developed on the basis of 11 389 patients in GRACE
and validated in subsequent GRACE and GUSTO (Global
Utilization of Streptokinase and TPA for Occluded Coro-
nary Arteries) IIb cohorts and predicts in-hospital death in
patients with STEMI, NSTEMI, or UA (C statistic0.83).
The 8 variables used in the GRACE risk model are older
age (OR 1.7 per 10 years), Killip class (OR 2.0 per class),
systolic blood pressure (OR 1.4 per 20 mm Hg decrease),
ST-segment deviation (OR 2.4), cardiac arrest during
presentation (OR 4.3), serum creatinine level (OR 1.2 per
1 mg per dL increase), positive initial cardiac markers (OR
1.6), and heart rate (OR 1.3 per 30-bpm increase). The sum
of scores is applied to a reference nonogram to determine
the corresponding all-cause mortality from hospital dis-
charge to 6 months. The GRACE clinical application tool
can be downloaded to a handheld PDA (personal digital
sive Strategies (Patients With UA/NSTEMI)
sed Update Recommendation Comments
trategy is indicated for patients with
o serious comorbidity† and who have
ble to PCI and who have
ive therapy (see Table 3 and Section
07 UA/NSTEMI Guidelines).14 (Level of
Modified recommendation*
intervention (or CABG) is recommended
with 1- or 2-vessel CAD with or
imal left anterior descending CAD but
ble myocardium and high-risk criteria
(Level of Evidence: B)
New recommendation*
intervention (or CABG) is recommended
with multivessel coronary disease with
my, with normal LV function, and
s. (Level of Evidence: A)
New recommendation*
GP IIb/IIIa inhibitor is useful in UA/
oing PCI. (Level of Evidence: A) See
13 of the 2007 ACC/AHA 2007 UA/
New recommendation*
gy (i.e., diagnostic angiography with
cularization) is indicated in UA/NSTEMI
ctory angina or hemodynamic or
hout serious comorbidities or
h procedures). (Level of Evidence: B)
New recommendation*al Inva
PCI Focu
Class I
ive PCI s
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coronary
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testing.
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 Table 2. Continued
2005 PCI Guideline Update Recommendation 2007 PCI Focused Update Recommendation Comments
Class IIa
It is reasonable that PCI be performed in patients with UA/NSTEMI
and single-vessel or multivessel CAD who are undergoing
medical therapy with focal saphenous vein graft lesions or
multiple stenoses who are poor candidates for reoperative
surgery. (Level of Evidence: C)
1. Percutaneous coronary intervention is reasonable for focal
saphenous vein graft lesions or multiple stenoses in
UA/NSTEMI patients who are undergoing medical therapy and
who are poor candidates for reoperative surgery. (Level of
Evidence: C)
Modified recommendation*
In the absence of high-risk features associated with UA/NSTEMI, it
is reasonable to perform PCI in patients with amenable lesions
and no contraindication for PCI with either an early invasive or
early conservative strategy. (Level of Evidence: B)
Deleted recommendation*
2. Percutaneous coronary intervention (or CABG) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without
significant proximal left anterior descending CAD but with a
moderate area of viable myocardium and ischemia on
noninvasive testing. (Level of Evidence: B)
New recommendation*
3. Percutaneous coronary intervention (or CABG) can be
beneficial compared with medical therapy for UA/NSTEMI
patients with 1-vessel disease with significant proximal left
anterior descending CAD. (Level of Evidence: B)
New recommendation*
Use of PCI is reasonable in patients with UA/NSTEMI with
significant left main CAD (greater than 50% diameter stenosis)
who are candidates for revascularization but are not eligible for
CABG. (Level of Evidence: B)
4. Use of PCI is reasonable in patients with UA/NSTEMI with
significant left main CAD (greater than 50% diameter stenosis)
who are candidates for revascularization but are not eligible
for CABG or who require emergency intervention at angiography
for hemodynamic instability. (Level of Evidence: B)
2005 recommendation remains current in
2007 PCI Update but receives additional
wording.
Class IIb
In the absence of high-risk features associated with UA/NSTEMI,
PCI may be considered in patients with single-vessel or
multivessel CAD who are undergoing medical therapy and who
have 1 or more lesions to be dilated with a less than optimal
likelihood of success. (Level of Evidence: B)
1. In the absence of high-risk features associated with
UA/NSTEMI, PCI may be considered in patients with single-
vessel or multivessel CAD who are undergoing medical
therapy and who have 1 or more lesions to be dilated with a
reduced likelihood of success. (Level of Evidence: B)
Modified recommendation*
PCI may be considered in patients with UA/NSTEMI who are
undergoing medical therapy who have 2- or 3-vessel disease,
significant proximal LAD CAD, and treated diabetes or abnormal
LV function. (Level of Evidence: B)
2. PCI may be considered in patients with UA/NSTEMI who are
undergoing medical therapy who have 2- or 3-vessel disease,
significant proximal left anterior descending CAD, and treated
diabetes or abnormal LV function, with anatomy suitable for
catheter-based therapy. (Level of Evidence: B)
2005 recommendation remains current in
2007 PCI Update but receives additional
wording.
3. In initially stabilized patients, an initially conservative (i.e., a
selectively invasive) strategy may be considered as a
treatment strategy for UA/NSTEMI patients (without serious
comorbidities or contraindications to such procedures†) who
have an elevated risk for clinical events (see Table 3)
including those who are troponin positive. (Level of Evidence:
B). The decision to implement an initial conservative (versus
initial invasive) strategy‡ in these patients may be made by
considering physician and patient preference. (Level of
Evidence: C)
New recommendation*
4. An invasive strategy may be reasonable in patients with
chronic renal insufficiency. (Level of Evidence: C)
New recommendation*
Class III
1. Percutaneous coronary intervention (or CABG) is not
recommended for patients with 1- or 2-vessel CAD without
significant proximal left anterior descending CAD with no
current symptoms or symptoms that are unlikely to be due to
myocardial ischemia and who have no ischemia on
noninvasive testing. (Level of Evidence: C)
New recommendation*
T-eleva
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 assistant) to be used at the bedside and is available at
www.outcomes-umassmed.org/grace (Figure 1).21 An
analysis comparing the 3 risk scores (TIMI, GRACE, and
PURSUIT) concluded that all 3 demonstrated good predic-
tive accuracy for death and MI at 1 year, thus identifying
patients who might be likely to benefit from aggressive
therapy, including early myocardial revascularization.22
Table 3. Selection of Initial Treatment Strategy:
Invasive Versus Conservative Strategy
Preferred Strategy Patient Characteristics
Invasive Recurrent angina or ischemia at rest or with low-level
activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of HF or new or worsening mitral
regurgitation
High-risk findings from noninvasive testing
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Prior CABG
High-risk score (e.g., TIMI, GRACE)
Reduced LV function (LVEF less than 40%)
Conservative Low-risk score (e.g., TIMI, GRACE)
Patient or physician preference in absence of high-risk
features
Reprinted from the ACC/AHA 2007 UA/NSTEMI Guidelines.14
CABG indicates coronary artery bypass graft surgery; GRACE, Global Registry
of Acute Coronary Events; HF, heart failure; LV, left ventricular; LVEF, left
ventricular ejection fraction; PCI, percutaneous coronary intervention; TIMI,
Table 2. Continued
2005 PCI Guideline Update Recommendation 2007
In the absence of high-risk features associated with UA/NSTEMI,
PCI is not recommended for patients with UA/NSTEMI who have
single-vessel or multivessel CAD and no trial of medical therapy,
or who have 1 or more of the following:
2. In the absence
UA/NSTEMI, P
NSTEMI who h
trial of medica
following:
a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with morphology
that conveys a low likelihood of success. (Level of Evidence: C)
c. A high risk of procedure-related morbidity or mortality.
(Level of Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis).
(Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG. (Level of
Evidence: B)
a. Only a sm
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*Based on the ACC/AHA 2007 UA/NSTEMI Guidelines.14
†For example, severe hepatic, pulmonary, or renal failure, or active/inopera
‡Diagnostic angiography with intent to perform revascularization.
CABG indicates coronary artery bypass graft; CAD, coronary artery disease;
IV, intravenous; LAD, left anterior descending; LV, left ventricular; MR, mitral re
Thrombolysis in Myocardial Infarction; and UA/NSTEMI, unstable angina/non–SThrombolysis In Myocardial Infarction; TnI, troponin I; and TnT, troponin T.The electrocardiogram (ECG) provides unique and im-
portant diagnostic and prognostic information (see also
Section 2.1 below). Accordingly, ECG changes have been
incorporated into quantitative decision aids for the triage
of patients who present with chest discomfort.23 Although
ST elevation carries the highest early risk of death, ST
depression on the presenting ECG portends the highest risk
Table 4. TIMI Risk Score for Unstable Angina/
Non–ST-Elevation Myocardial Infarction
TIMI Risk Score
All-Cause Mortality, New or Recurrent MI, or
Severe Recurrent Ischemia Requiring Urgent
Revascularization Through
14 Days After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
The TIMI risk score is determined by the sum of the presence of 7 variables
at admission; 1 point is given for each of the following variables: age 65 years
or older; at least 3 risk factors for CAD; prior coronary stenosis of 50% or more;
ST-segment deviation on ECG presentation; at least 2 anginal events in prior 24
hours; use of aspirin in prior 7 days; and elevated serum cardiac biomarkers.
Prior coronary stenosis of 50% or more remained relatively insensitive to
missing information and remained a significant predictor of events. Reprinted
with permission from Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk
score for unstable angina/non-ST elevation MI: a method for prognostication
and therapeutic decision making. JAMA. 2000;284:835–42.15 Copyright ©
2000 American Medical Association.
CAD indicates coronary artery disease; ECG, electrocardiogram; MI, myo-
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 of death at 6 months, with the degree of ST-segment
depression showing a strong relationship to outcome.24
The recommendations in the ACC/AHA 2007 UA/
NSTEMI Guidelines14 recognize recent data from the
ACUITY (Acute Catheterization and Urgent Intervention
Triage strategY) trial, which showed that in patients with
ACS who were undergoing invasive treatment, bivalirudin
alone was associated with rates of ischemia similar to
those treated with glycoprotein (GP) IIb/IIIa inhibitors
plus heparin and significantly less bleeding.25
The ACC/AHA 2007 UA/NSTEMI Guidelines cite a progres-
sively greater benefit from newer, more aggressive therapies
such as low-molecular-weight heparin (LMWH),16,26 platelet
GP IIb/IIIa inhibition,27 and an invasive strategy28 with increas-
ing risk score.
2.1. Electrocardiogram
The ECG lies at the center of the decision pathway for the
Figure 1. GRACE Prediction Score Card and Nomogram for All-C
sion.20 Copyright © 2004 American Medical Association.evaluation and management of patients with acute ischemicdiscomfort (Table 5). The diagnosis of MI is confirmed with
serial cardiac biomarkers in more than 90% of patients who
present with ST-segment elevation greater than or equal to 1 mm
(0.1 mV) in at least 2 contiguous leads, and such patients should
be considered candidates for acute reperfusion therapy. Patients
who present with ST-segment depression are initially considered
to have either UA or NSTEMI; the distinction between the 2
diagnoses is ultimately based on the detection of markers of
myocardial necrosis in the blood.29–31
Up to 25% of patients with NSTEMI and elevated
CK-MB go on to develop Q-wave MI during their hospital
stay, whereas the remaining 75% have non–Q-wave MI.
Acute fibrinolytic therapy is contraindicated for ACS
patients without ST-segment elevation, except for those
with electrocardiographic true posterior MI manifested as
ST-segment depression in 2 contiguous anterior precordial
leads and/or isolated ST-segment elevation in posterior
chest lead.32–34 Inverted T waves may also indicate UA/
Mortality From Discharge to 6 Months. Reprinted with permis-auseNSTEMI. In patients suspected of having ACS on clinical
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 grounds, marked (greater than or equal to 2 mm [0.2 mV])
symmetrical precordial T-wave inversion strongly suggests
acute ischemia, particularly that associated with a critical
stenosis of the left anterior descending coronary artery
(LAD).35 Patients with this ECG finding often exhibit
hypokinesis of the anterior wall and are at high risk if
given medical treatment alone.36 Revascularization will
often reverse both the T-wave inversion and wall-motion
disorder.37 Nonspecific ST-segment and T-wave changes,
usually defined as ST-segment deviation less than 0.5 mm
(0.05 mV) or T-wave inversion less than or equal to 2 mm
(0.2 mV), are less diagnostically helpful than the foregoing
findings. Established Q waves greater than or equal to 0.04
second are also less helpful in the diagnosis of UA,
although by suggesting prior MI, they do indicate a high
likelihood of significant coronary artery disease (CAD).
Isolated Q waves in lead III may be a normal finding,
especially in the absence of repolarization abnormalities in
any of the inferior leads. A completely normal ECG in a
patient with chest pain does not exclude the possibility of
ACS, because 1% to 6% of such patients eventually are
proven to have had an MI (by definition, NSTEMI), and at
least 4% will be found to have UA.38 – 40
In addition to the presence or absence of ST-segment
deviation or T-wave inversion patterns noted earlier, there is
evidence that the magnitude of the ECG abnormality provides
important prognostic information. Thus, Lloyd-Jones et al.41
reported that the diagnosis of acute non–Q-wave MI was 3 to
4 times more likely in patients with ischemic discomfort who
had at least 3 ECG leads that showed ST-segment depression
and maximal ST depression of greater than or equal to 0.2
mV. Investigators from the TIMI III Registry42 reported that
the 1-year incidence of death or new MI in patients with at
least 0.5 mm (0.05 mV) of ST-segment deviation was 16.3%
compared with 6.8% for patients with isolated T-wave
changes and 8.2% for patients with no ECG changes.
Cardiogenic shock can occur in the setting of both STEMI
and NSTEMI, and there is high mortality and morbidity in
Table 5. Likelihood That Signs and Symptoms Represent an Acu
Feature
High Likelihood
Any of the following:
History Chest or left arm pain or discomfort as
chief symptom reproducing prior
documented angina
Known history of CAD, including MI
Examination Transient MR murmur, hypotension,
diaphoresis, pulmonary edema, or rales
ECG New, or presumably new, transient ST-
segment deviation (1 mm or greater) or
T-wave inversion in multiple precordial
leads
Cardiac markers Elevated cardiac TnI, TnT, or CK-MB
Modified from reference 46. In the public domain.
CAD indicates coronary artery disease; CK-MB, MB fraction of creatine kin
troponin I; and TnT, troponin T.each. The SHOCK (SHould we emergently revascularizeOccluded Coronaries for cardiogenic shocK) study43 found
that approximately 20% of all cardiogenic shock complicat-
ing MI was associated with NSTEMI. The GUSTO-II44 and
PURSUIT45 trials found that cardiogenic shock occurs in up
to 5% of patients with NSTEMI and that mortality rates are
greater than 60%. Thus, hypotension and evidence of organ
hypoperfusion can occur and constitute a medical emergency
in NSTEMI.
2.1.1. Comparison of Early Invasive and Initial
Conservative Strategies for UA/NSTEMI
Prior meta-analyses concluded that routine invasive ther-
apy (the “invasive” or “early” strategy triages patients to
undergo an invasive diagnostic evaluation without first
getting a noninvasive stress test or without failing medical
treatment [i.e., an initial conservative diagnostic strategy
or sometimes now known as the “selective invasive strat-
egy”]14) is better than an initial conservative or selectively
invasive approach (the “initial conservative strategy” [also
referred to as “selective invasive management”] calls for
proceeding with an invasive evaluation only for those
patients who fail medical therapy [refractory angina or
angina at rest or with minimal activity despite rigorous
medical therapy] or in whom objective evidence of isch-
emia [dynamic ECG changes, high-risk stress test] is
identified14). Mehta et al47 concluded that the routine
invasive strategy resulted in an 18% relative reduction in
death or MI, including a significant reduction in MI alone.
The routine invasive arm was associated with higher
in-hospital mortality (1.8% versus 1.1%), but this disad-
vantage was more than compensated for by a significant
reduction in mortality between discharge and the end of
follow-up (3.8% versus 4.9%). In those analyses, the
invasive strategy was associated with less angina and
fewer rehospitalizations than the conservative pathway.
Patients undergoing routine invasive treatment also had
improved quality of life.
In contrast to these findings, other studies, most recently
onary Syndrome Secondary to CAD
Intermediate Likelihood
bsence of high-likelihood
features and presence
of any of the following:
Low Likelihood
Absence of high- or
intermediate-likelihood features
but may have the following:
left arm pain or discomfort as
ptom
ter than 70 years
mellitus
Probable ischemic symptoms in
absence of any intermediate-likelihood
characteristics
Recent cocaine use
iac vascular disease Chest discomfort reproduced by
palpation
aves
ssion 0.5 to 1 mm or T-wave
greater than 1 mm
T-wave flattening or inversion less than
1 mm in leads with dominant R waves
Normal ECG
Normal
G, electrocardiogram; MI, myocardial infarction; MR, mitral regurgitation; TnI,te Cor
A
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chief sym
Age grea
Male sex
Diabetes
Extracard
Fixed Q w
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inversion
Normal
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 coronary Syndromes), have favorably highlighted a strategy
of selective invasive therapy.48 In ICTUS, 1200 high-risk
ACS patients without ST-segment elevation were randomized
to receive routine invasive versus selective invasive manage-
ment and followed up for 1 year with respect to the combined
incidence of death, MI, and ischemic rehospitalization. All
patients were treated with optimal medical therapy that
included aspirin, clopidogrel, LMWH, and lipid-lowering
therapy; abciximab was given to those undergoing revascu-
larization. At the end of 1 year, there was no significant
difference in the composite end point between groups. This
study suggests that a selective invasive strategy could be
reasonable for ACS patients. A possible explanation for the
lack of benefit of the invasive approach in this trial (and other
trials)49 could be related to the relatively high rate of
revascularization actually performed in patients treated in the
selective invasive arm (47%), thereby reducing observed
differences between treatment strategies,22 and to the lower
event rate (lower-risk population) than in other studies.
Results were unchanged during longer-term follow-up.50,51
Nevertheless, ICTUS required troponin positivity for entry.
Thus, troponin alone might no longer be an adequate criterion
for strategy selection, especially with increasingly sensitive
troponin assays. The degree of troponin elevation and other
high-risk clinical factors taken together should be considered
in selecting a treatment strategy. The ICTUS trial was
relatively underpowered for hard end points, and it used a
controversial definition for post procedural MI (i.e., even
minimal asymptomatic CK-MB elevation).48,50,51
Additionally, 1-year follow-up may be inadequate to fully
realize the long-term impact and benefit of the routine
invasive strategy. In the RITA-3 trial (Third Randomized
Intervention Trial of Angina), 5-year but not 1-year event
rates favored the early invasive arm (see Figure 2 and text
below).52 In ICTUS, however, results were maintained during
a 3-year follow-up.53
Thus, the 2007 UA/NSTEMI Guidelines14 recommend that
in initially stabilized UA/NSTEMI patients, an initial conser-
vative (selective invasive) strategy may be considered as an
alternative treatment option. The writing committee also
believes that additional comparative trials of the selective
invasive with the routine initial invasive strategies are indi-
cated, using aggressive contemporary medical therapies in
both arms, including routine dual antiplatelet therapy (DAT)
in medically treated patients as well as aggressive lipid
lowering and other updated secondary prevention measures.
Nevertheless, a meta-analysis of contemporary randomized
trials in NSTEMI, including ICTUS, currently support long-
term mortality and morbidity benefits of an early invasive
compared with an initial conservative strategy.54 Nonfatal MI
at 2 years (7.6% vs. 9.1%, respectively; RR 0.83 [95% CI
0.72 to 0.96]; p  0.012) and hospitalization (at 13 months;
RR  0.69 [95% CI 0.65 to 0.74]; p less than 0.0001) also
were reduced by an early invasive strategy (Figure 3). A
separate review of contemporary randomized trials in the
stent era using the Cochrane Database arrived at similar
conclusions.55 Details of selected contemporary trials of
invasive versus conservative strategies may be found in the
ACC/AHA 2007 UA/NSTEMI Guidelines.14Thus, the FRISC-II (Fragmin and Fast Revascularisation
during InStability in Coronary artery disease)56 and TAC-
TICS (Treat Angina with Aggrastat and Determine Cost of
Therapy with an Invasive or Conservative Strategy)-TIMI
1828 trials showed a benefit in patients assigned to invasive
strategy. In contrast to earlier trials, a large majority of
patients undergoing percutaneous coronary intervention
(PCI) in these 2 trials received coronary stenting as opposed
to balloon angioplasty alone. Also, there was a differential
rate of thienopyridine use between the 2 arms; only stented
patients were treated. In FRISC-II, the invasive strategy
involved treatment with LMWH, aspirin, nitrates, and beta
blockers for an average of 6 days in the hospital before
coronary angiography, an approach that would be difficult to
adopt in US hospitals. In TACTICS-TIMI 18, treatment
included the GP IIb/IIIa antagonist tirofiban, which was
administered for an average of 22 hours before coronary
angiography. The routine use of the GP IIb/IIIa inhibitor in
this trial may have eliminated the excess risk of early (within
7 days) MI in the invasive arm, a risk that was observed in
FRISC-II and other trials in which there was no routine
“upstream” use of a GP IIb/IIIa blocker. Therefore, an
invasive strategy is associated with a better outcome in
UA/NSTEMI patients at high risk as defined in Table 3 and
as demonstrated in TACTICS-TIMI 18 when a GP IIb/IIIa
Figure 2. Cumulative Risk of Death or Myocardial Infarction
in RITA-3. Top: Cumulative risk of death or myocardial infarction
in the RITA-3 trial of patients with non-ST acute coronary syn-
drome. Bottom: Cumulative risk of death in the RITA-3 trial of
patients with non-ST acute coronary syndromes. Reprinted with
permission.52inhibitor is used.28 Although the benefit of intravenous GP
tory Unstable angina in geographically isolated areas without
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 IIb/IIIa inhibitors is established for UA/NSTEMI patients
undergoing PCI, the optimal time to start these drugs before
the procedure has not been established. In the PURSUIT
trial,45 in patients with UA/NSTEMI who were admitted to
community hospitals, the administration of eptifibatide was
associated with a reduced need for transfer to tertiary referral
centers and improved outcomes.57
The RITA-3 trial52 compared early and conservative ther-
apy in 1810 moderate-risk patients with ACS. Patients with
positive cardiac biomarkers (CK-MB greater than 2 times the
upper limit of normal at randomization) were excluded from
randomization, as were those with new Q waves, MI within 1
month, PCI within 1 year, and any prior coronary artery
bypass graft (CABG). The combined end point of death,
nonfatal MI, and refractory angina was reduced from 14.5%
to 9.6% by early invasive treatment. The benefit was driven
primarily by a reduction in refractory angina. There was a late
divergence of the curves, with reduced 5-year death and MI in
the early invasive arm (Figure 2).
In the VINO trial (Value of first day angiography/ angio-
plasty In evolving Non-ST segment elevation myocardial
infarction: Open multicenter randomized trial),58 131 patients
with NSTEMI were randomized to cardiac catheterization on
the day of admission versus conservative therapy. Despite the
fact that 40% of the conservatively treated patients crossed
over to revascularization by the 6-month follow-up, there was
a significant reduction in death or reinfarction for patients
assigned to early angiography and revascularization (6%
versus 22%).
The ISAR-COOL (Intracoronary Stenting with Antithrom-
botic Regimen Cooling-off) trial59 randomized 410
intermediate- to high-risk patients to very early angiography
and revascularization versus a delayed invasive strategy. All
patients were treated with intensive medical therapy that
included aspirin, heparin, clopidogrel (600-mg loading dose),
and the intravenous GP IIb/IIIa receptor inhibitor tirofiban. In
the very early arm, patients underwent cardiac catheterization
at a mean time of 2.4 hours versus 86 hours in the delayed
invasive arm. The very early invasive strategy was associated
with significantly better outcome at 30 days, as measured by
reduction in death and large MI (5.9% versus 11.6%). More
importantly, the benefit seen was attributable to a reduction in
events before cardiac catheterization, which raises the possi-
bility that there is a hazard associated with a “cooling-down”
period.
2.1.2. Selection for Coronary Angiography
In contrast to the noninvasive tests, coronary angiography
provides detailed structural information to allow assessment
of prognosis and provide direction for appropriate manage-
ment. When combined with left ventricular (LV) angiogra-
phy, it also allows an assessment of global and regional LV
function. Indications for coronary angiography are interwo-
ven with indications for possible therapeutic plans, such as
PCI or CABG.
Cardiac Surgery; UA/NSTEMI, unstable angina/non-ST-segment
elevation myocardial infarction: Open multicenter randomizedFigure 3. Relative Risk of Outcomes With Early Invasive Versus
Conservative Therapy in UA/NSTEMI. A: Relative risk of all-
cause mortality for early invasive therapy compared with con-
servative therapy at a mean follow-up of 2 years. B: Relative
risk of recurrent nonfatal myocardial infarction for early invasive
therapy compared with conservative therapy at a mean fol-
low-up of 2 years. C: Relative risk of recurrent unstable angina
resulting in rehospitalization for early invasive therapy compared
with conservative therapy at a mean follow-up of 13 months.54
CI indicates confidence interval; FRISC-II, FRagmin and fast
Revascularization during InStability in Coronary artery disease;
ICTUS, Invasive versus Conservative Treatment in Unstable cor-
onary Syndromes; ISAR-COOL, Intracoronary Stenting with Anti-
thrombotic Regimen COOLing-off; RITA-3, Third Randomized
Intervention Trial of Angina; RR, relative risk; TIMI-18, Thrombol-
ysis In Myocardial Infarction-18; TRUCS, Treatment of Refrac-trial. Modified with permission.54
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 Coronary angiography is usually indicated in patients with
UA/NSTEMI who either have recurrent symptoms or isch-
emia despite adequate medical therapy or are at high risk as
categorized by clinical findings (HF, serious ventricular
arrhythmias) or noninvasive test findings (significant LV
dysfunction: ejection fraction less than 0.35, large anterior or
multiple perfusion defects) (Tables 6, 7, and 8). Patients with
UA/NSTEMI who have had previous PCI or CABG also
should generally be considered for early coronary angiogra-
phy unless prior coronary angiography data indicate that
further revascularization is not likely to be possible. The
placement of an intra-aortic balloon pump (IABP) may allow
coronary angiography and revascularization in those with
hemodynamic instability. Patients with suspected Prinzmet-
al’s variant angina also are candidates for coronary angiog-
raphy.
In all cases, the general indications for coronary angiogra-
phy and revascularization are tempered by individual patient
characteristics and preferences. Patient and physician judg-
ments regarding risks and benefits are particularly important
Table 7. Noninvasive Test Results That Predict High Risk for
Adverse Outcome (Left Ventricular Imaging)
Stress Radionuclide
Ventriculography Stress Echocardiography
Exercise EF 0.50 or less Rest EF 0.35 or less
Rest EF 0.35 or less Wall-motion score index greater than 1
Fall in EF 0.10 or greater
Modified from references 61 and 62.
Table 6. Noninvasive Risk Stratification
High risk (greater than 3% annual mortality rate)
Severe resting LV dysfunction (LVEF less than 0.35)
High-risk treadmill score (score –11 or less)
Severe exercise LV dysfunction (exercise LVEF less than 0.35)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple perfusion defects of moderate size
Large, fixed perfusion defect with LV dilation or increased lung uptake (thallium-201)
Stress-induced moderate perfusion defect with LV dilation or increased lung uptake (t
Echocardiographic wall-motion abnormality (involving more than 2 segments) develop
120 bpm)
Stress echocardiographic evidence of extensive ischemia
Intermediate risk (1% to 3% annual mortality rate)
Mild/moderate resting LV dysfunction (LVEF 0.35 to 0.49)
Intermediate-risk treadmill score (11 to 5)
Stress-induced moderate perfusion defect without LV dilation or increased lung intake
Limited stress echocardiographic ischemia with a wall-motion abnormality only at hig
Low risk (less than 1% annual mortality rate)
Low-risk treadmill score (score 5 or greater)
Normal or small myocardial perfusion defect at rest or with stress*
Normal stress echocardiographic wall motion or no change of limited resting wall-mo
*Although published data are limited, patients with these findings will prob
resting LV dysfunction (LVEF less than 0.35). Reprinted from reference 60.
LV indicates left ventricular, and LVEF, left ventricular ejection fraction.EF indicates ejection fraction.for patients who might not be candidates for coronary
revascularization, such as very frail older adults and those
with serious comorbid conditions (i.e., severe hepatic, pul-
monary, or renal failure or active or inoperable cancer).
2.1.3. Chronic Kidney Disease
The following recommendations have been added to the PCI
Focused Update in accordance with new recommendations
appearing in the 2007 UA/NSTEMI Guidelines14 (Table 9).
Supporting text from that guidelines statement is presented in
the following paragraphs.
Chronic kidney disease (CKD) is not only a coronary risk
equivalent for ascertainment of coronary risk but also a risk
factor for the development and progression of cardiovascular
disease (CVD).63 CKD constitutes a risk factor for adverse
outcomes after MI,64 including NSTEMI and other coronary
patient subsets. In the highly validated GRACE risk score, serum
creatinine is 1 of 8 independent predictors of death.20,65 In 1
recent study, even early CKD constituted a significant risk factor
for cardiovascular events and death.64,66 CKD also predicts an
increase in recurrent cardiovascular events.67 Cardiovascular
Table 8. Noninvasive Test Results That Predict High Risk for
Adverse Outcome on Stress Radionuclide Myocardial Perfusion
Imaging
Abnormal myocardial tracer distribution in more than 1 coronary artery region at rest or
with stress or a large anterior defect that reperfuses
Abnormal myocardial distribution with increased lung uptake
Cardiac enlargement
01)
ow dose of dobutamine (10 mg/kg per min or less) or at a low heart rate (less than
-201)
of dobutamine involving less than or equal to 2 segments
rmalities during stress*
be at low risk in the presence of either a high-risk treadmill score or severehallium-2
ing with l
(thallium
her doses
tion abno
ably notModified from reference 61.
tion; an
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 death is 10 to 30 times higher in dialysis patients than in the
general population. The underrepresentation of patients with
renal disease in randomized controlled trials of CVD is a
concern.68 Current opinion and most of the limited evidence
available suggest that when appropriately monitored, cardiovas-
cular medications and interventional strategies can be applied
safely in those with renal impairment and provide therapeutic
benefit.64 However, not all recent evidence is consistent with this
premise: atorvastatin did not significantly reduce the primary
end point of cardiovascular death, nonfatal MI, or stroke in a
prospective randomized trial of patients with diabetes and
end-stage CKD who were undergoing hemodialysis.69 The
preference for primary PCI has also been questioned.70
Particularly in the setting of ACS, bleeding complications
are higher in this patient subgroup because of platelet
dysfunction and dosing errors; benefits of fibrinolytic therapy,
antiplatelet agents, and anticoagulants can be negated or
outweighed by bleeding complications; and renin-
angiotensin-aldosterone inhibitors can impose a greater risk
because of the complications of hyperkalemia and worsening
renal function in the patient with CKD. Angiography carries
an increased risk of contrast-induced nephropathy; the usual
benefits of PCI can be lessened or abolished; and PCI in
patients with CKD is associated with a higher rate of early
and late complications of bleeding, restenosis, and death.68
Thus, identification of CKD is important in that it represents
an ACS subgroup with a far more adverse prognosis but for
whom interventions have less certain benefit.
Coronary arteriography is a frequent component of the care
of ACS patients. As such, contrast-induced nephropathy can
constitute a serious complication of diagnostic and interven-
tional procedures. In patients with CKD or CKD and diabe-
tes, isosmolar contrast material lessens the rise in creatinine
and is associated with lower rates of contrast-induced ne-
phropathy than low-osmolar contrast media. This has been
documented in a randomized clinical trial (RECOVER [Renal
Toxicity Evaluation and Comparison Between Visipaque
(Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal
Insufficiency Undergoing Coronary Angiography]) compar-
ing iodixanol with ioxaglate71 and in a meta-analysis of 2727
patients from 16 randomized clinical trials.72
Identification of patients with CKD as recommended in the
AHA Science Advisory on Detection of CKD in patients with
or at increased risk of CVD should guide the use of isosmolar
contrast agents.63 The advisory, which was developed in
Table 9. Indications for Chronic Kidney Disease
2005 PCI Guideline Update Recommendation 200
1. Creatinine cle
patients, and
adjusted app
2. In chronic kid
isosmolar co
(Level of Evid
*Based on the ACC/AHA 2007 UA/NSTEMI Guidelines.14
CKD indicates chronic kidney disease; PCI, percutaneous coronary intervencollaboration with the National Kidney Foundation, recom-mends that all patients with CVD be screened for evidence of
kidney disease by estimating glomerular filtration rate, testing
for microalbuminuria, and measuring the albumin-to-
creatinine ratio. A glomerular filtration rate of less than 60 ml
per min per 1.73 square meters of body surface should be
regarded as abnormal. Furthermore, the albumin-to-creatinine
ratio should be used to screen for the presence of kidney
damage in adult patients with CVD, with values greater than
30 mg of albumin per 1 g of creatinine considered abnormal.
A diagnosis of renal dysfunction is critical to proper medical
therapy for UA/NSTEMI. Many cardiovascular drugs used in
patients with UA/NSTEMI are renally cleared; their doses
should be adjusted for estimated creatinine clearance [see also
Section 3 of the 2007 UA/NSTEMI Guidelines14]. In a large
community-based registry study, 42% of patients with UA/
NSTEMI received excessive initial dosing of at least 1 antiplate-
let or antithrombin agent (unfractionated heparin [UFH],
LMWH, or GP IIb/IIIa inhibitor).73 Renal insufficiency was an
independent predictor of excessive dosing. Dosing errors pre-
dicted an increased risk of major bleeding. Clinical studies and
labeling that defines adjustments for several of these drugs have
been based on the Cockcroft-Gault formula for estimating
creatinine clearance, which is not identical to the Modification of
Diet and Renal Disease (MDRD) formula. Use of the Cockcroft-
Gault formula to generate dose adjustments is recommended.
The impact of renal dysfunction on biomarkers of necrosis (i.e.,
troponin) is discussed in Section 2.2.8.2.1 of the 2007 UA/
NSTEMI Guidelines.14
To increase the meager evidence base and to optimize care for
this growing high-risk population, the recognition of CKD
patients with or at risk of CVD and the inclusion and reporting
of renal disease in large CVD trials must be increased in the
future.
3. Facilitated PCI
Facilitated PCI refers to a strategy of planned immediate PCI
after administration of an initial pharmacological regimen
intended to improve coronary patency before the procedure.
These regimens have included high-dose heparin, platelet GP
IIb/IIIa inhibitors, full-dose or reduced-dose fibrinolytic ther-
apy, and the combination of a GP IIb/IIIa inhibitor with a
reduced-dose fibrinolytic agent (e.g., fibrinolytic dose typi-
cally reduced 50%). Facilitated PCI should be differentiated
from primary PCI without fibrinolytic therapy, from primary
used Update Recommendation Comments
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 from early or delayed PCI after successful fibrinolytic ther-
apy, and from rescue PCI after unsuccessful fibrinolytic
therapy. Potential advantages of facilitated PCI include ear-
lier time to reperfusion, smaller infarct size, improved patient
stability, lower infarct artery thrombus burden, greater pro-
cedural success rates, higher TIMI flow rates, and improved
survival rates. Potential risks include increased bleeding
complications, especially in older patients; potential limita-
tions include added cost.
Despite the potential advantages, clinical trials of facili-
tated PCI have not demonstrated any benefit in reducing
infarct size or improving outcomes. The largest of these was
the ASSENT-4 (Assessment of the Safety and Efficacy of a
New Treatment Strategy with Percutaneous Coronary Inter-
vention) PCI trial,5 in which 1667 patients were randomized
to full-dose tenecteplase and PCI versus primary PCI. The
trial was terminated prematurely because of a higher in-
hospital mortality rate in the facilitated PCI group (6% vs.
3%, p  0.01). The primary end point, a composite of death,
shock, and congestive heart failure within 90 days, was
significantly higher with facilitated PCI than with primary
PCI (18.6% vs. 13.4%; p  0.0045), and there was a trend
toward higher 90-day mortality (6.7% vs. 4.9%; p  0.14).
Defenders of the facilitated PCI strategy point out that the
absence of an infusion of heparin after bolus administration
and of a loading dose of clopidogrel, plus prohibition of GP
IIb/IIIa inhibitors except in bail-out situations, made adjunc-
tive antithrombotic therapy suboptimal for the facilitated PCI
group. Moreover, the median treatment delay between tenect-
eplase and PCI was only 104 minutes, and mortality rates
with facilitated PCI were higher in PCI centers. Whether
earlier (pre-hospital) administration of fibrinolytic therapy,
better antithrombotic therapy, longer delays to PCI, or selec-
tive use of PCI as a rescue strategy would make the facilitated
PCI strategy beneficial is unclear and requires further study.
On the basis of these data, however, facilitated PCI offered no
clinical benefit.
Keeley and coworkers performed a quantitative review of
17 trials that compared facilitated PCI and primary PCI74
(Figure 4). Included were 9 trials with GP IIb/IIIa inhibitors
Table 10. Updates to Section 5.4.3: PCI for STEMI in Conjunction
2005 PCI Guideline Update Recommendation 2007 PC
Facilitated PCI might be performed as a reperfusion
strategy in higher-risk patients when PCI is not
immediately available and bleeding risk is low. (Level of
Evidence: B)
1. Facilitated PC
fibrinolytic th
reperfusion s
present:
a. Patients ar
b. PCI is not
and
c. Bleeding ri
poorly con
(Level of E
1. A planned re
fibrinolytic th
harmful. (LevLOE indicates level of evidence; PCI, percutaneous coronary intervention; and STEMalone (n  1148), 6 trials with fibrinolytic therapy (including
ASSENT-4 PCI) (n  2953), and 2 trials with a fibrinolytic
agent plus a GP IIb/IIIa inhibitor (n  399). Facilitated PCI
with fibrinolytic therapy had significantly higher rates of
mortality, nonfatal reinfarction, urgent target vessel revascu-
larization, total and hemorrhagic stroke, and major bleeding
compared with primary PCI. There were no differences in
efficacy or safety when facilitated PCI with a GP IIb/IIIa
inhibitor was compared with primary PCI.
A planned reperfusion strategy using full-dose fibrinolytic
therapy followed by immediate PCI may be harmful (Table
10). Nevertheless, selective use of the facilitated strategy with
regimens other than full-dose fibrinolytic therapy in high-risk
subgroups of patients (large MI or hemodynamic or electrical
instability) with low bleeding risk who present to hospitals
without PCI capability might be performed when transfer
delays for primary PCI are anticipated. Although the quanti-
tative analysis showed no advantage for pretreatment with a
GP IIb/IIIa inhibitor, neither did it document any major
disadvantage. The use of GP IIb/IIIa inhibitors, particularly
abciximab, during primary PCI is well established. Further
trials of reduced-dose fibrinolytic therapy, with or without GP
IIb/IIIa inhibitors, are in progress and may yield different
efficacy and/or safety results. For further clarification, please
see Section 6.3.1.6.2.1 of the 2004 ACC/AHA Guidelines for
the Management of Patients With ST-Elevation Myocardial
Infarction.75
Pharmacological reperfusion with full-dose fibrinolysis is
not uniformly successful in restoring antegrade flow in the
infarct artery. In such situations, a strategy of prompt coro-
nary angiography with intent to perform PCI is frequently
contemplated. In certain patients, such as those with cardio-
genic shock (especially in those less than 75 years of age),
severe congestive heart failure/pulmonary edema, or hemo-
dynamically compromising ventricular arrhythmias (regard-
less of age), a strategy of coronary angiography with intent to
perform PCI is a useful approach regardless of the time since
initiation of fibrinolytic therapy, provided further invasive
management is not considered futile or unsuitable given the
clinical circumstances (Table 11). Further discussion of the
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 management of such patients may be found in Section 5.4.4
(which has been updated in this document) of the 2005 PCI
Guideline Update.13a
4. Rescue PCI
In other patients who do not exhibit the clinical instability
noted above, PCI may also be reasonable if there is clinical
suspicion of failure of fibrinolysis. This is referred to as
rescue PCI. Critical to the success of rescue PCI is the initial
clinical identification of patients who are suspected of having
failed reperfusion with full-dose fibrinolysis. Because the
presence or absence of ischemic discomfort may be unreli-
able for identifying failed reperfusion, clinicians should
search for evidence of inadequate ST-segment resolution on
the 12-lead ECG. Operationally, the 12-lead ECG should be
scrutinized after adequate time has elapsed before making the
judgment that fibrinolytic therapy has not been effective.
Although earlier periods have been used in some studies, the
writing committee felt that 90 minutes after initiation of
fibrinolysis provided the best time for evaluating the need for
rescue PCI: hence, if there is less than 50% ST resolution in
the lead showing the greatest degree of ST-segment elevation
at presentation, fibrinolytic therapy has likely failed to pro-
duce reperfusion.
The 2005 PCI Guideline Update13a recommendations for
rescue PCI were based on observational data and 2 small
randomized clinical trials (n 179) from the early 1990s.94,95
More recently, MERLIN (Middlesbrough Early Revascular-
ization to Limit Infarction) (n  307) and REACT (Rescue
Angioplasty versus Conservative Treatment or Repeat
Thrombolysis) (n 427) and 3 meta-analyses have refocused
attention on rescue PCI.96–100 This subject has been studied
with fewer than 1000 patients enrolled in randomized trials.
In the period between trials studying rescue PCI, there was a
transition between angiographic and electrocardiographic diag-
nosis to detect failed reperfusion. Importantly, in the earlier
studies, rescue PCI was performed in infarct arteries with TIMI0/1 flow, often after a protocol-mandated 90-minute angiogram.
In MERLIN and REACT, however, patients were randomized if
they had less than 50% ST-segment elevation resolution at 60 or
90 minutes, respectively. Many patients had patent infarct
arteries at angiography; only 54% of patients in MERLIN and
74% of patients in REACT (which required less than TIMI grade
3 flow for PCI) actually underwent PCI. From a procedural
standpoint, stents have replaced balloon angioplasty, antiplatelet
therapy has improved with the addition of a thienopyridine agent
and often a GP IIb/IIIa receptor antagonist, and procedural
success rates are higher.
Despite these historical differences, recent data support the
initial observation that rescue PCI decreases adverse clinical
events compared with medical therapy. In the Wijeysundera
meta-analysis100) (Figure 5, there was a trend toward reduced
mortality rates with rescue PCI from 10.4% to 7.3% (RR 0.69
[95% CI 0.46 to 1.05]; p  0.09), reduced reinfarction rates
from 10.7% to 6.1% (RR 0.58 [95% CI 0.35 to 0.97]; p 
0.04), and reduced HF rates from 17.8% to 12.7% (RR 0.73
[95% CI 0.54 to 1.00]; p  0.05). These event rates suggest
that high-risk patients were selected for enrollment, so these
data do not define the role of rescue PCI in lower-risk
patients. Also, the benefits of rescue PCI need to be balanced
against the risk. There was an excess occurrence of stroke in
2 trials (10 events versus 2 events), but the majority were
thromboembolic rather than hemorrhagic, and the sample size
was small, so more data are required to define this risk. There
was also an increase of 13% in absolute risk of bleeding,
suggesting that adjustments in antithrombotic medication
dosing are needed to improve safety. It should be noted that
the majority of patients who underwent rescue PCI received
streptokinase as fibrinolytic therapy.
Given the association between bleeding events and
subsequent ischemic events,103 it might be reasonable to
select moderate- and high-risk patients for PCI after
fibrinolysis and to treat low-risk patients with medical
Figure 4. Short-Term Death in Patients Treated
With Facilitated Or Primary PCI. Trials were clas-
sified by facilitated regimen. Diamonds and
squares indicate odds ratios. Lines indicate 95%
confidence intervals. Reprinted with permission.74therapy. As noted above, patients with cardiogenic shock,
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 severe HF, or hemodynamically compromising ventricular
arrhythmias are excellent candidates. An electrocardio-
graphic estimate of potential infarct size in patients with
persistent ST-segment elevation (less than 50% resolution
Table 11. Updates to Section 5.4.4: PCI After Failed Fibrinolysis
2005 PCI Guideline Update Recommendation 2007 PCI
Rescue PCI should be performed in patients less than 75 years
old with ST elevation or left bundle-branch block who develop
shock within 36 hours of MI and are suitable for
revascularization that can be performed within 18 hours of
shock unless further support is futile because of the patient’s
wishes or contraindications/unsuitability for further invasive
care. (Level of Evidence: B)
1. A strategy of c
perform PCI (o
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and onset of symptoms within 12 hours. (Level of Evidence: B)
Rescue PCI is reasonable for selected patients 75 years or older
with ST elevation or left bundle-branch block or who develop
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 with symptom resolution, improving ST-segment elevation
(less than 50% resolution), or inferior MI localized to 3
ECG leads probably should not be referred for angiogra-
phy. Likewise, it is doubtful that PCI of a branch artery
(diagonal or obtuse marginal branch) will change progno-
sis in the absence of the high-risk criteria noted above.
5. PCI After Fibrinolysis or for Patients Not
Undergoing Primary Reperfusion
The open artery hypothesis suggests that late patency of an
infarct artery is associated with improved LV function,
increased electrical stability, and provision of collateral
vessels to other coronary beds for protection against future
events (see Table 12). The OAT (Occluded Artery Trial)12
tested the hypothesis that routine PCI for total occlusion 3 to
28 days after MI would reduce the composite of death,
reinfarction, or Class IV heart failure. Stable patients (n 
2166) with an occluded infarct artery after MI (about 20% of
whom received fibrinolytic therapy for the index event) were
randomized to optimal medical therapy and PCI with stenting
or optimal medical therapy alone. The qualifying period of 3
to 28 days was based on calendar days; thus, the minimal time
from symptom onset to angiography was just over 24 hours.
Inclusion criteria included total occlusion of the infarct-
related artery with TIMI grade 0 or 1 antegrade flow and LV
ejection fraction (LVEF) less than 50% or proximal occlusion
of a major epicardial artery with a large risk region. Exclusion
criteria included NYHA Class III or IV heart failure, serum
creatinine greater than 2.5 mg per dL, left main or 3-vessel
disease, clinical instability, or severe inducible ischemia on
stress testing if the infarct zone was not akinetic or dyskinetic.The 4-year cumulative end point was 17.2% in the PCI group
and 15.6% in the medical therapy group (HR 1.16 [95% CI
0.92 to 1.45] p  0.2). Reinfarction rates tended to be higher
in the PCI group, which may have attenuated any benefit in
LV remodeling. There was no interaction between treatment
effect and any subgroup variable.
Preclinical studies have suggested that late opening of
an occluded infarct artery may reduce adverse LV remod-
eling and preserve LV volumes. However, 5 previous
clinical studies in 363 patients have demonstrated incon-
sistent improvement in LVEF or LV end-systolic and
end-diastolic volumes after PCI. The largest of these, the
DECOPI (DEsobstruction COronaire en Post-Infarctus)
trial, found a higher LVEF at 6 months with PCI.105
TOSCA-2 (Total Occlusion Study of Canada)13 enrolled
381 stable patients in a mechanistic ancillary study of OAT
and had the same eligibility criteria.12 The PCI procedure
success rate was 92% and the complication rate was 3%,
although 9% had periprocedural MI as measured by
biomarkers. At 1 year, patency rates (n  332) were higher
with PCI (83% vs. 25%; p less than 0.0001), but each
group (n  286) had equivalent improvement in LVEF
(4.2% vs. 3.5%; p  0.47). There was modest benefit of
PCI on preventing LV dilation over 1 year in a multivariate
model, but only 42% had paired volume determinations, so
it is unclear whether this finding extends to the whole
cohort. The potential benefit of PCI in attenuating remod-
eling may have been decreased by periprocedural MI and
the high rate of use of beta blockers and ACE inhibitors.
There was no significant interaction between treatment
Figure 5. Efficacy End Points for Rescue PCI Versus Con-
servative Therapy. CI indicates confidence interval; MER-
LIN, Middlesbrough Early Revascularization to Limit
Infarction trial; NNT, number needed to treat; PCI, percuta-
neous coronary intervention; REACT, Rescue Angioplasty
versus Conservative Treatment or Repeat Thrombolysis
trial; RESCUE, Randomized Comparison of Rescue Angio-
plasty with Conservative Management of Patients with
Early Failure of Thrombolysis for Acute Anterior Myocardial
Infarction trial; RR, relative risk; and TAMI, Thrombolysis
and Angioplasty in Myocardial Infarction study. Reprinted
with permission.100effect and time, infarct artery, or infarct size.
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 6. Ancillary Therapy for Patients Undergoing
PCI for STEMI
The 2007 STEMI Guidelines Focused Update106 includes a
new section on the use of anticoagulant therapy for patients
undergoing PCI to establish reperfusion for STEMI. The
recommendations associated with PCI are summarized in
Table 13.
Full discussion of the background and basis of these
recommendations may be found in the 2007 STEMI
Guidelines Focused Update. When moving to PCI after
fibrinolytic therapy, those patients who received upstream
UFH or enoxaparin can continue to receive those antico-
agulants in a seamless fashion (i.e., without crossover to
another agent) under the dosing regimens listed in the
recommendations.106,107 On the basis of reports of catheter
thrombosis with fondaparinux alone during primary PCI in
OASIS-6 (Organization for Assessment of Strategies for
Ischemic Syndromes)7 and the experience with fondapa-
rinux in the OASIS-5 trial,108 the STEMI focused update
writing group recommended that fondaparinux should not
be used as the sole anticoagulant during PCI but should be
coupled with an additional agent that has anti-IIa activity
Table 12. Updates to Section 5.4.5: PCI After Successful Fibrino
2005 PCI Guideline Update Recommendation 20
In patients whose anatomy is suitable, PCI should be performed when
there is objective evidence of recurrent MI. (Level of Evidence: C)
1. In pati
perfor
recurr
In patients whose anatomy is suitable, PCI should be performed for
moderate or severe spontaneous or provocable myocardial ischemia
during recovery from STEMI. (Level of Evidence: B)
2. In pati
perfor
provoc
STEMI
In patients whose anatomy is suitable, PCI should be performed for
cardiogenic shock or hemodynamic instability. (Level of Evidence: B)
3. In pati
perfor
instab
It is reasonable to perform routine PCI in patients with LV ejection fraction
less than or equal to 0.40, HF, or serious ventricular arrhythmias. (Level
of Evidence: C)
1. It is re
LV eje
seriou
It is reasonable to perform PCI when there is documented clinical heart
failure during the acute episode, even though subsequent evaluation
shows preserved LV function (LV ejection fraction greater than 0.40).
(Level of Evidence: C)
2. It is re
docum
episod
preser
0.40).
PCI might be considered as part of an invasive strategy after fibrinolytic
therapy. (Level of Evidence: C)
1. PCI of
patent
may b
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1. PCI of
hours
asymp
they a
do not
Eviden
COR/LOE indicates class of recommendation/level of evidence; HF, hear
ST-elevation myocardial infarction.to ameliorate the risk of catheter complications. Althoughbivalirudin or UFH are potential options for supplemental
anticoagulation with fondaparinux, the available experi-
ence, albeit limited, is largely with UFH. The only avail-
able data from the CREATE (Clinical Trial of Reviparin
and Metabolic Modulation in Acute Myocardial Infarction
Treatment) trial that bear on this point are with UFH.109
Given the complexities of the characteristics of the indi-
vidual agents and their actions on the coagulation cascade,
clinicians are cautioned about extrapolating any of the obser-
vations with agents discussed in this update to other antico-
agulant regimens. In particular, as noted by the Food and
Drug Administration (FDA), the LMWHs are sufficiently
distinct that they should be evaluated individually rather than
considered as a class of interchangeable agents.110
7. Antiplatelet Therapy
The 2005 PCI Guideline Update13a recommended aspirin
antiplatelet therapy of 325 mg, which was based primarily on
results from the TAXUS IV and SIRIUS trials.111–128 Since
that time, experience has been gained with doses of aspirin
ranging from 75 mg to 325 mg (see Table 14 for further
information and Table 15 for a list of the trials). No
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 aspirin (75 mg to 100 mg) with higher-dose aspirin (162 mg
to 325 mg) in subacute or late stent thrombosis with the
incidence of bleeding as the initial course of therapy after
placement of drug-eluting stents (DES). Two major
trials129,130 involving patients not undergoing placement of
DES report an increase in risk of bleeding on higher-dose
aspirin. No conclusive data are available regarding higher-
dose aspirin and subacute stent thrombosis among patients
who are considered aspirin resistant.
Continued treatment with the combination of aspirin and
clopidogrel after PCI appears to reduce rates of cardiovascular
ischemic events.130,131 On the basis of randomized clinical trial
protocols, aspirin 162 mg to 325 mg daily should be given for at
least 1 month after implantation of a bare-metal stent (BMS), 3
months after implantation of a sirolimus-eluting stent (SES), and
6 months after implantation of a paclitaxel-eluting stent (PES),
after which daily long-term use of aspirin should be continued
indefinitely at a dose of 75 mg to 162 mg. In patients for whom
there is concern about bleeding, the opinion of the writing group
is that lower doses of aspirin—75 mg to 162 mg—can be used.
Likewise, clopidogrel 75 mg daily should be given for a
minimum of 1 month after implantation of a BMS [mini-
mum 2 weeks for patients at significant increased risk of
bleeding132] and for 12 months after implantation of a SES
or PES and ideally in all patients post PCI who are not at
high risk of bleeding. Under urgent circumstances that
prevent the use of clopidogrel for 1 year, the duration
studied for FDA approvals was 3 months for an SES and 6
months for a PES. The optimal duration of clopidogrel
therapy after 1 year has not been established and should
depend on the judgment of the risk– benefit ratio for the
Table 13. Ancillary Therapy
2005 PCI Guideline Update
Recommendation 2007 PCI Focu
1. For patients undergoing PCI after
following dosing recommendation
a. For prior treatment with UFH, a
support the procedure, taking i
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be used in patients treated pre
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Evidence: C)
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should be administered. (Level of
*Based on 2007 STEMI Focused Update.106
GP indicates glycoprotein; IV, intravenous; PCI, percutaneous coronary inteindividual patient. Predictors of late stent thrombosis haveincluded stenting of small vessels, multiple lesions, long
stents, overlapping stents, ostial or bifurcation lesions,
prior brachytherapy, suboptimal stent result, low ejection
fraction, advanced age, diabetes mellitus, renal failure,
ACS, and premature discontinuation of antiplatelet
agents.133,134 Patients should be counseled on the need for
and risks of DAT before placement of intracoronary stents,
especially a DES, and alternative therapies to pursue if
they are unwilling or unable to comply with the recom-
mended duration of DAT. To reduce the incidence of
bleeding complications associated with DAT, lower-dose
aspirin (75 mg to 162 mg daily) is reasonable for long-term
therapy.135,136 Given the importance of a 1-year course of
DAT, it is recommended that elective surgery be post-
poned for 1 year, and among those patients for whom
surgery cannot be deferred, aspirin therapy should be
considered during the perioperative period in high-risk
patients with DES.133
Several investigations have explored various loading
doses of clopidogrel before or during PCI. Consistent
findings are that compared with a 300-mg loading dose,
doses of either 600 or 900 mg achieve greater degrees of
platelet inhibition with less variability among patients.137
Fewer patients may demonstrate “resistance” or nonre-
sponsiveness to clopidogrel following the 600-mg dose.
There appears to be no significant additive value of the
900-mg dose over the 600-mg dose.137
The 600-mg dose appears to achieve maximum inhibi-
tion more rapidly than the 300-mg dose.138 Superior
clinical outcomes at 30 days, primarily reduction in evi-
dence of MI, have been reported after the 600-mg dose
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 Table 14. Updates to Section 6.2.1: Oral Antiplatelet Therapy
2005 PCI Guideline Update Recommendation 2007 PCI Focused Update Recommendation Comments
Class I
Patients already taking daily chronic aspirin therapy should
take 75 to 325 mg of aspirin before the PCI procedure is
performed. (Level of Evidence: A)
1. Patients already taking daily long-term aspirin
therapy should take 75 mg to 325 mg of
aspirin before PCI is performed. (Level of
Evidence: A)
2005 recommendation remains current in
2007 PCI Update
Patients not already taking daily chronic aspirin therapy should
be given 300 to 325 mg of aspirin at least 2 hours and
preferably 24 hours before the PCI procedure is performed.
(Level of Evidence: C)
2. Patients not already taking daily long-term
aspirin therapy should be given 300 mg to 325
mg of aspirin at least 2 hours and preferably
24 hours before PCI is performed. (Level of
Evidence: C)
2005 recommendation remains current in
2007 PCI Update
After the PCI procedure, in patients with neither aspirin
resistance, allergy, nor increased risk of bleeding, aspirin 325
mg daily should be given for at least 1 month after bare-metal
stent implantation, 3 months after sirolimus-eluting stent
implantation, and 6 months after paclitaxel-eluting stent
implantation, after which daily chronic aspirin use should be
continued indefinitely at a dose of 75 to 162 mg. (Level of
Evidence: B)
3. After PCI, in patients without allergy or
increased risk of bleeding, aspirin 162 mg to
325 mg daily should be given for at least 1
month after BMS implantation, 3 months after
sirolimus-eluting stent implantation, and 6
months after paclitaxel-eluting stent
implantation, after which daily long-term
aspirin use should be continued indefinitely at
a dose of 75 mg to 162 mg. (Level of
Evidence: B)
Modified recommendation (changed text)
A loading dose of clopidogrel should be administered before
PCI is performed. (Level of Evidence: A) An oral loading dose
of 300 mg, administered at least 6 hours before the
procedure, has the best established evidence of efficacy.
(Level of Evidence: B)
4. A loading dose of clopidogrel,* generally 600
mg, should be administered before or when
PCI is performed. (Level of Evidence: C) In
patients undergoing PCI within 12 to 24 hours
of receiving fibrinolytic therapy, a clopidogrel
oral loading dose of 300 mg may be
considered. (Level of Evidence: C)
Modified recommendation (changed LOE and
text)
In patients who have undergone PCI, clopidogrel 75 mg daily
should be given for at least 1 month after bare-metal stent
implantation (unless the patient is at increased risk of
bleeding; then it should be given for a minimum of 2 weeks),
3 months after sirolimus stent implantation, and 6 months
after paclitaxel stent implantation, and ideally up to 12
months in patients who are not at high risk of bleeding. (Level
of Evidence: B)
5. For all post-PCI stented patients receiving a
DES, clopidogrel 75 mg daily should be given
for at least 12 months if patients are not at
high risk of bleeding. For post-PCI patients
receiving a BMS, clopidogrel should be given
for a minimum of 1 month and ideally up to
12 months (unless the patient is at increased
risk of bleeding; then it should be given for a
minimum of 2 weeks). (Level of Evidence: B)
Modified recommendation (changed text)
Class IIa
If clopidogrel is given at the time of procedure,
supplementation with GP IIb/IIIa receptor antagonists can be
beneficial to facilitate earlier platelet inhibition than with
clopidogrel alone. (Level of Evidence: B)
1. If clopidogrel is given at the time of procedure,
supplementation with GP IIb/IIIa receptor
antagonists can be beneficial. (Level of
Evidence: B)
Modified recommendation (changed text)
For patients with an absolute contraindication to aspirin, it is
reasonable to give a 300-mg loading dose of clopidogrel,
administered at least 6 hours before PCI, and/or GP IIb/IIIa
antagonists, administered at the time of PCI. (Level of
Evidence: C)
2. For patients with an absolute contraindication
to aspirin, it is reasonable to give a 300-mg to
600-mg loading dose of clopidogrel,
administered at least 6 hours before PCI, and/
or GP IIb/IIIa antagonists, administered at the
time of PCI. (Level of Evidence: C)
2005 recommendation remains current in
2007 PCI Update
3. In patients for whom the physician is
concerned about risk of bleeding, a lower dose
of 75 mg to 162 mg of aspirin is reasonable
during the initial period after stent
implantation. (Level of Evidence: C)
New recommendation
Class IIb
1. Continuation of clopidogrel therapy beyond 1
year may be considered in patients undergoing
DES placement. (Level of Evidence: C)
New recommendation
*Some uncertainty exists about optimal loading dose of clopidogrel. Randomized trials establishing its efficacy and providing data on bleeding risks used a loading
dose of 300 mg orally followed by a daily oral dose of 75 mg. Higher oral loading doses such as 600 mg or 900 mg of clopidogrel more rapidly inhibit platelet
aggregation and achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral loading doses have
not been rigorously established.
BMS indicates bare-metal stent; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous; LOE, level of evidence; PCI, percutaneous coronary intervention; and
STEMI, ST-elevation myocardial infarction.
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 effect was not confirmed in 1 investigation.139 No excess
hazard has been reported with the 600-mg compared with
the 300-mg dose for patients treated with fibrinolytic
therapy; however, loading doses greater than 300 mg have
not been studied.140 Larger trials will more fully evaluate
higher doses of clopidogrel on clinical events, as well as
further evaluate safety (e.g., bleeding). The OASIS-7 trial
is comparing 600-mg with 300-mg loading doses of
clopidogrel and will provide further evidence about the
optimal treatment strategy.
There is agreement that the loading dose should be
administered before PCI. What is unclear is the precise
time when the loading dose must be given to achieve a
desirable therapeutic effect. Evidence from the CREDO
(Clopidogrel for the Reduction of Events During Observa-
tion) trial suggests that with a 300-mg dose, 6 hours is the
minimum time.131 With the 600-mg dose, 2 hours may be
sufficient (141), although maximal platelet inhibition may
not be achieved until 3 to 4 hours.142
Long-term clopidogrel therapy alone may not achieve
adequate inhibition for PCI. Patients on long-term therapy
with clopidogrel experience significant additional incre-
mental inhibition of platelet aggregation when given a
Table 15. Aspirin Dosages of Major Clinical Trials Involving PCI
Trial Name Stents Compared
T
Pa
RAVEL111 SES versus BMS
E-SIRIUS112 SES versus BMS
TAXUS I113 PES versus BMS
TAXUS II114 PES versus BMS
TAXUS III115 PES for ISR only
C-SIRIUS116 SES versus BMS
DELIVER117 ACHIEVE versus ML PENTA 1
ELUTES118 PES versus BMS
SIRIUS119 SES versus BMS 1
TAXUS IV120 PES versus BMS EXPRESS 1
ISAR-DESIRE121 SES versus PES versus
balloon angioplasty
ISAR-DIABETES122 SES versus PES
SIRTAX123 SES versus PES 1
TAXi124 SES versus PES
TAXUS V125 PES versus BMS 1
TAXUS VI126 PES versus BMS
REALITY127 SES versus PES 1
TAXUS V ISR128 PES versus VBT for ISR
ACHIEVE indicates a brand-name paclitaxel-coated stent; BMS, bare-met
European evaLUation of pacliTaxel Eluting Stent; E-SIRIUS, European Sirolimus-E
REstenosis; ISAR-DIABETES, Paclitaxel-Eluting Stent Versus Sirolimus-Eluting S
ISR, in-stent restenosis; IV, intravenous; ML PENTA, multilink stainless steel ba
RAVEL, A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard
Head-to-Head Comparison of the Sirolimus-Eluting Stent (Cypher) and the Paclit
in Coronary Lesions; SIRTAX, Sirolimus-Eluting Stent Compared With Paclitaxe
the real world of interventional cardiology; TAXUS V ISR, Paclitaxel-Eluting Steloading dose.143 In patients treated with fibrinolytic ther-apy, however, loading doses of greater than 300 mg have
not been studied.144
8. Bare-Metal and Drug-Eluting Stents
8.1. Selection of a Bare-Metal or Drug-Eluting
Stent
Observational studies indicate that physicians routinely im-
plant stents when performing coronary interventions. Two
types of stents are available: BMS and DES. Drug-eluting
stents have become increasingly popular as standard therapy.
In 2005, a sampling of 140 US hospitals indicated that 94%
of patients treated with a stent received at least 1 DES.145
More recently, however, because of concerns about stent
thrombosis and the mandate that each DES-treated patient
take prolonged DAT, the proportion of DES use has declined
to 60% to 70%.
The results of the clinical trials that led to FDA approval
of the DES provide support for its use in suitable patients.
Extended follow-up of the initial investigated patient
cohorts to 4 years confirms the sustained benefit of DES in
decreasing the need for repeat revascularization but with-
Duration of Treatment Aspirin Dose
Indefinite 100 mg once a day
Indefinite 100 mg once a day
Greater than or equal to 12
months
Greater than 80 mg once
a day
Indefinite 75 mg once a day
Not stated Greater than or equal to
75 mg
Indefinite 81 to 325 mg once a day
1 year 325 mg once a day
3 months Not stated
Indefinite 325 mg once a day
Indefinite 325 mg once a day
Indefinite 500 mg IV during; 100
mg bid after
Indefinite 100 mg twice a day
Indefinite 100 mg once a day
“Long term” 100 mg once a day
Indefinite 325 mg once a day
Greater than or equal to 6 months 75 mg at least 2 hours
prior; greater than or
equal to 75 mg after
Indefinite 100 mg once a day
Indefinite (9-month minimum,
indefinite recommended)
325 mg once a day
; C-SIRIUS, Canadian Sirolimus-Eluting Stent in Coronary Lesions; ELUTES,
tent in Coronary Lesions; h, hour; ISAR-DESIRE, Drug-Eluting Stents for in-stent
the Prevention of Restenosis in Diabetic Patients With Coronary Artery Disease;
l stent; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stent;
or Coronary Revascularization; REALITY, Prospective Randomized Multi-Center
ting Stent (TAXUS); SES, sirolimus-eluting stent; SIRIUS, Sirolimus-Eluting Stent
Stent for Coronary Revascularization; TAXi, Paclitaxel and sirolimus stents in
sus Brachytherapy for In-Stent Restenosis; and VBT, vascular brachytherapy.otal
tients
238
352
61
536
28
100
043
190
058
314
300
250
012
202
172
448
353
396
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 trials in selected clinical subsets such as BMS in-stent
restenosis, total occlusions, diabetes mellitus, and small-
diameter arteries have also demonstrated the value of DES
and have prompted physicians to extend the application of
DES beyond the narrow patient populations included in the
initial approval trials.122,126,149 –154 The duration of
follow-up of these “off-label” studies and the small number
of patients enrolled, however, limit the detection of subtle
differences in important end points such as stent thrombo-
sis, death, or MI.
It is important to recognize certain differences between the
BMS and DES when selecting a stent for an individual patient
or lesion. First, in general, a DES may be more difficult to
implant than a BMS. The DES has a polymer coating that
stiffens the stent and makes it less conformable. Accordingly,
one reason for using a BMS is that it can be used in patients
in whom a DES cannot be implanted successfully. Second,
the DES is substantially more expensive than the BMS. When
financial resources are limited, use of the DES may be
rationed, with implantation only in those patients at greatest
risk for restenosis.
A third but very important difference relates to the
inhibition of endothelial coverage of the DES and the need
for extended DAT (Table 16). After introduction of the
BMS, it was associated with a disturbingly high incidence
of stent thrombosis.141 Stent thrombosis often presented as
MI or even death and usually occurred in the first 30 days
after implantation. Changes in technique such as high
inflation pressure and intravascular ultrasound (IVUS)-
Table 16. Updates to Section 7.3.5: Drug-Eluting and Bare-Meta
2005 PCI Guideline Update Recommendation 2007
A drug-eluting stent (DES) should be considered as an
alternative to the bare-metal stent in subsets of
patients in whom trial data suggest efficacy. (Level of
Evidence: A)
1. A DES shou
in those pa
favorable e
A)
2. Before imp
should disc
duration of
comply wit
Evidence: B
3. In patients
are likely to
which DAT
months, co
a BMS or p
provisional
of a DES. (
1. In patients
risk of blee
aspirin is r
A DES may be considered for use in anatomic
settings in which the usefulness, effectiveness, and
safety have not been fully documented in published
trials. (Level of Evidence: C)
1. A DES may
settings in
favorable b
trials. (Leve
BMS indicates bare-metal stent; DAT, dual antiplatelet therapy; DES, drug-guided deployment and use of concomitant combinedaspirin and thienopyridine therapy substantially reduced
the incidence of stent thrombosis to a clinically acceptable
level.155 Importantly, the requisite duration of DAT was
only 4 weeks, and some advocated only 2 weeks. The
importance of DAT in preventing stent thrombosis was
further strengthened by the outcome of patients for whom
DAT was discontinued prematurely because of the need for
those patients to undergo surgical procedures. These pa-
tients experienced a disturbingly high incidence of stent
thrombosis.156 The critical role of DAT in preventing stent
thrombosis was also noted among patients with BMS who
had received brachytherapy for in-stent restenosis. Pre-
sumably these patients were less likely to develop subse-
quent neointimal coverage of the endoluminal stent surface
and were accordingly then more susceptible to stent
thrombosis.
In the initial randomized trials that compared the DES with
BMS, DAT was administered for 30 days to 6 months. The
most recent guidelines update describes a minimum duration
of 3 months of DAT for an SES and 6 months for a PES. On
the basis of results from other trials that suggest a sustained
benefit of DAT, these guidelines further state that ideally
DAT should be extended to 12 months. Although these
recommendations were to some extent arbitrary, subsequent
studies have confirmed that premature discontinuation of
DAT, that is, at a time less than “minimal duration” (3 months
for the SES and 6 months for the PES) was highly associated
with stent thrombosis.157
The tight relationship between DAT and stent thrombosis
s
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 implications for selecting the type of stent deployed at the
time of PCI. For example, the clinician should not select a
DES for a patient who does not have access to DAT for
financial reasons or who is unlikely to be compliant in taking
DAT. One study revealed that 14% of patients had stopped
DAT 1 month after implantation of the DES.158 Also,
implantation of a BMS may be more appropriate in a patient
with a known increased risk of bleeding. In situations such as
these, the consequences of developing restenosis are consid-
ered less untoward than those of stent thrombosis or signifi-
cant bleeding.
Furthermore, prescribed premature discontinuation of DAT
in patients treated with a DES should not be done casually.
For example, routine dental procedures should not justify
cessation of DAT even though it is anticipated DAT will be
subsequently resumed.133 Consideration should be given to
delay scheduling of elective procedures that normally warrant
discontinuation of antiplatelet agents. The benefit of DES in
reducing the need for target vessel revascularization (TVR)
also should be taken into account. Some registries have
shown 1-digit TVR rates with the BMS, and the absolute
reduction in these events using the DES depends on patient
and lesion characteristics.
There are also concerns related to the appropriate duration
of DAT. More recently, the occurrence of late (up to 1 year)
or very late (beyond 1 year) stent thrombosis among DES-
treated patients has been described.159 One database analysis
suggests that extended use of DAT may have value in
preventing late stent thrombosis, whereas others disagree.160
Outcomes of patients in the initial FDA-approval trials
to 4 years provides reassurance that, at least for those types
of patients, despite a small excess of stent thrombosis,
there appears to be no increase in death or MI when
comparing DES-treated groups with BMS-treated groups.
As noted, protocol-recommended DAT in these patients
was not more than 6 months, although extended DAT was
not prohibited. (These results are observed despite a
significant excess occurrence of stent thrombosis among
patients who received a paclitaxel stent.) Some have
postulated that the substantial additional revascularization
procedures experienced by BMS patients were associated
with a small but significant excess rate of death and MI that
offset any deaths or MIs that may have occurred in the DES
group related to stent thrombosis.
Less data are available regarding the outcomes of
patients who receive a DES for an “off-label” indication.
Such patients have characteristics of their coronary dis-
ease, for example, a lesion in an artery less than 2.5 mm in
diameter, very long lesions, bifurcation lesions, or a
clinical syndrome such as acute MI, that were excluded in
the FDA-approval trials. Reports from large observational
studies indicate that “off-label” patients may experience
higher rates of repeat revascularization and death and MI
at 1 year than DES patients with “on-label” features.
Importantly, a similar relationship is observed for patients
treated with a BMS. In addition, there appears to be a
significant association between “off-label” use and stent
thrombosis. Accordingly, the appropriate selection forDAT among “off-label” DES patients may be different than
for “on-label” patients.
At this point in time, 12 months of DAT is recom-
mended for all patients who receive a DES120 (see Section
6.2.1) unless there is a high risk of bleeding. The benefits
and indications for treatment with DAT beyond 1 year in
patients with DES are the subject of ongoing studies.
Low-dose aspirin should be continued indefinitely. For
patients with clinical features associated with stent throm-
bosis, such as renal insufficiency, diabetes, or procedural
characteristics such as multiple stents or treatment of a
bifurcation lesion, extended DAT beyond 1 year may be
reasonable. The risk of stent thrombosis needs to be
balanced with other medical conditions and nonmedical
factors that might affect the risk-benefit ratio of DAT
versus other therapies. Finally, certain DES-treated pa-
tients have already discontinued DAT 1 year after stent
implantation. No information yet supports restarting DAT
in these patients.
9. Secondary Prevention
Table 17 presents revised recommendations based on the
2006 AHA/ACC Secondary Prevention Guidelines for
Patients with Coronary and Other Atherosclerotic Vascular
Diseases.11 This table replaces Table 26 from the 2005 PCI
Guideline Update.13a Classes of recommendation and a
corresponding level of evidence have been added for all
recommendations. There is a new recommendation for
annual influenza vaccination, and the section on antiplate-
let agents/anticoagulants has been modified slightly to
reflect the recent evidence on aspirin dosage in patients
who have undergone PCI with stent placement. Other
changes since publication of the 2006 ACC/AHA Second-
ary Prevention Guidelines include the addition of recom-
mended daily physical activity and a Class IIa recommen-
dation for lowered low-density lipoprotein cholesterol.
Staff
American College of Cardiology Foundation
John C. Lewin, MD, Chief Executive Officer
Charlene May, Director, Clinical Policy and Documents
Lisa Bradfield, Associate Director, Practice Guidelines
Kristen N. Fobbs, MS, Senior Specialist, Practice
Guidelines
Mark D. Stewart, MPH, Associate Director, Evidence-
Based Medicine
Sue Keller, BSN, MPH, Senior Specialist, Evidence-
Based Medicine
Erin A. Barrett, Senior Specialist, Clinical Policy and
Documents
American Heart Association
M. Cass Wheeler, Chief Executive Officer
Rose Marie Robertson, MD, FACC, FAHA, Chief Science
Officer
Judy Bezanson, DSN, CNS, RN, Science and MedicineAdvisor
284 Circulation January 15, 2008
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 Table 17. Comprehensive Risk Reduction for Patients With Coronary and Other Vascular Disease After PCI
2005 PCI Recommendations 2007 PCI Recommendations 2007 COR and LOE Comments
Smoking
Goal: Complete cessation, no exposure to environmental tobacco smoke
Ask about tobacco status at every visit. 1. Status of tobacco use should be asked about at every
visit.
I (B) Modified recommendation
(changed text)
Strongly encourage patient and family to
stop smoking and avoid secondhand smoke.
2. Every tobacco user and family members who smoke
should be advised to quit at every visit.
I (B) No content change
Assess the tobacco user’s willingness to
quit.
3. The tobacco user’s willingness to quit should be
assessed.
I (B) No content change
Assist by counseling and developing a plan
for quitting.
4. The tobacco user should be assisted by counseling and
developing a plan for quitting.
I (B) No content change
Arrange follow-up, referral to special
programs, or pharmacological therapy
(including nicotine replacement and
bupropion).
5. Follow-up, referral to special programs, or
pharmacotherapy (including nicotine replacement and
pharmacological treatment) should be arranged.
I (B) No content change
Urge avoidance of exposure to
environmental tobacco smoke at work and
home.
6. Exposure to environmental tobacco smoke at work and
home should be avoided.
I (B) No content change
Blood Pressure Control
Goal: Less than 140/90 mm Hg or less than 130/80 mm Hg if patient has diabetes or chronic kidney disease
Initiate or maintain lifestyle modification
(weight control, increased physical activity,
alcohol moderation, moderate sodium
restriction, and emphasis on fruits,
vegetables, and low-fat dairy products) in all
patients.
1. For patients with blood pressure greater than or equal to
140/90 mm Hg (or greater than or equal to 130/80 mm
Hg for patients with diabetes or chronic kidney disease), it
is recommended to initiate or maintain lifestyle
modification—weight control; increased physical activity;
alcohol moderation; sodium reduction; and emphasis on
increased consumption of fresh fruits, vegetables, and
low-fat dairy products.
I (B) No content change
Add blood pressure medication,*
emphasizing the use of beta blockers and
inhibitors of the renin-angiotensin-
aldosterone system.
2. For patients with blood pressure greater than or equal to
140/90 mm Hg (or greater than or equal to 130/80 mm
Hg for patients with diabetes or chronic kidney disease), it
is useful as tolerated, to add blood pressure medication,
treating initially with beta blockers and/or ACE inhibitors,
with the addition of other drugs such as thiazides as
needed to achieve goal blood pressure.
I (A) Modified recommendation
(changed text)
Lipid Management
Goal: LDL-C substantially less than 100 mg per dL
(If triglycerides are greater than or equal to 200 mg per dL, non–HDL-C should be less than 130 mg per dL†.)
Start dietary therapy in all patients (less
than 7% of total calories as saturated fat
and less than
200 mg/d cholesterol).
1. Starting dietary therapy is recommended. Reduce intake
of saturated fats (to less than 7% of total calories), trans
fatty acids, and cholesterol (to less than 200 mg per day).
I (B) Modified recommendation
(changed text)
2. Adding plant stanol/sterols (2 g per day) and/or viscous
fiber (greater than 10 g per day) is reasonable to further
lower LDL-C.
IIa (A) New recommendation
Promote physical activity and weight
management.
3. Promotion of daily physical activity and weight
management is recommended.
I (B) Modified recommendation
(changed text)
Encourage increased consumption of
omega-3 fatty acids in fish‡ or 1 g/d
omega-3 fatty acids from supplements for
risk reduction (for treatment of elevated
triglycerides, higher doses are usually
necessary for risk reduction).
4. It may be reasonable to encourage increased consumption
of omega-3 fatty acids in the form of fish‡ or in capsules
(1 g per day) for risk reduction. For treatment of elevated
triglycerides, higher doses are usually necessary for risk
reduction.
IIb (B) No content change
Assess fasting lipid profile in all patients,
preferably within 24 hours of an acute
event. For hospitalized patients, initiate
lipid-lowering medication as recommended
below before discharge according to the
following guide:
5. A fasting lipid profile should be assessed in all patients
and within 24 hours of hospitalization for those with an
acute cardiovascular or coronary event. For hospitalized
patients, initiation of lipid-lowering medication is indicated
as recommended below before discharge according to the
following schedule:
I (A) Modified recommendation
(changed text)
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 Table 17. Continued
2005 PCI Recommendations 2007 PCI Recommendations 2007 COR and LOE Comments
LDL-C less than 100 mg/dL (baseline or on
treatment): Statins preferred to lower LDL-C.
● LDL-C should be less than 100 mg per dL. I (A) Modified recommendation
(changed text)
● Further reduction of LDL-C to less than 70 mg per dL is
reasonable.
IIa (A) New recommendation
If LDL-C is greater than or equal to 100
mg/dL (baseline or on treatment), initiate or
intensify LDL-C–lowering therapy with drug
treatment. May require combination therapy
with standard-dose ezetimide, bile acid
sequestrant, or niacin.
● If baseline LDL-C is greater than or equal to 100 mg per
dL, LDL-lowering drug therapy§ should be initiated.
I (A) Modified recommendation
(changed text)
● If on-treatment LDL-C is greater than or equal to 100
mg per dL, intensify LDL-lowering drug therapy (may
require LDL-lowering drug combination¶) is
recommended.
I (A) New recommendation
● If baseline LDL-C is 70 to 100 mg per dL, it is
reasonable to treat to LDL-C less than 70 mg per dL.
IIa (B) New recommendation
If triglycerides are greater than or equal to
150 mg/dL or HDL-C is less than 40 mg/dL,
emphasize weight management and
physical activity. Advise smoking cessation.
● If triglycerides are greater than or equal to 150 mg per
dL or HDL-C is less than 40 mg per dL, weight
management, physical activity, and smoking cessation
should be emphasized.
I (B) Modified recommendation
(changed text)
If triglycerides are 200 to 499 mg/dL: ● If triglycerides are 200 to 499 mg per dL††, non–HDL-C
target should be less than 130 mg per dL.
I (B) Modified recommendation
(changed text)
● If triglycerides are 200 to 499 mg per dL††, further
reduction of non–HDL-C to less than 100 mg per dL is
reasonable.
IIa (B) New recommendation
6. Therapeutic options to reduce non–HDL-C include:
● More intense LDL-C–lowering therapy is indicated. I (B) New recommendation
After LDL-C–lowering therapy,**†† consider
adding fibrate or niacin¶
● Niacin (after LDL-C–lowering therapy) can be beneficial. IIa (B) Modified recommendation
(changed text)
● Fibrate therapy‡‡ (after LDL-C–lowering therapy) can be
beneficial.
IIa (B) Modified recommendation
(changed text)
If triglycerides are greater than or equal to
500 mg/dL:
● Consider fibrate or niacin§ before LDL-C–
lowering therapy.¶††
● Consider omega-3 fatty acids as an
adjunct for high triglycerides.
7. If triglycerides are greater than or equal to 500 mg per
dL,††§§ therapeutic options indicated and useful to
prevent pancreatitis are fibrate§‡‡ or niacin§ before
LDL-lowering therapy, and treat LDL-C to goal after
triglyceride-lowering therapy. Achieving a non–HDL-C of
less than 130 mg per dL is recommended.
I (C) Modified recommendation
(changed text)
Physical Activity
Goal: 30 minutes 5 days per week; optimal daily
Cardiac rehabilitation programs are
recommended, particularly for patients with
multiple modifiable risk factors and/or
moderate- to high-risk patients for whom
supervised exercise training is warranted.
1. Advising medically supervised programs (cardiac
rehabilitation) for high-risk patients (e.g., recent acute
coronary syndrome or revascularization, heart failure) is
recommended.
I (B) Modified recommendation
(changed text)
Assess risk, preferably with exercise testing,
to guide prescription.
2. For all patients, it is recommended that risk be assessed
with a physical activity history and/or an exercise test to
guide prescription.
I (B) Modified recommendation
(changed text)
Encourage a minimum of 30 to 60 minutes
of activity, preferably daily or at least 5
days per week (brisk walking, jogging,
cycling, or other aerobic activity)
supplemented by an increase in daily
lifestyle activities (e.g., walking breaks at
work, gardening, and household work).
3. For all patients, encouraging 30 to 60 minutes of
moderate-intensity aerobic activity is recommended, such
as brisk walking on most—preferably all—days of the
week, supplemented by an increase in daily lifestyle
activities (e.g., walking breaks at work, gardening, and
household work).
I (B) Modified recommendation
(changed text)
Encourage resistance training 2 days per
week.
4. Encouraging resistance training 2 days per week may be
reasonable.
IIb (C) No content change
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 Table 17. Continued
2005 PCI Recommendations 2007 PCI Recommendations 2007 COR and LOE Comments
Weight Management
Goal: BMI: 18.5 to 24.9 kg/m2
Waist circumference: men less than 40 inches (102 cm), women less than 35 inches (89 cm)
Calculate BMI and measure waist
circumference as part of evaluation. Monitor
response of BMI and waist circumference to
therapy.
1. It is useful to assess BMI and/or waist circumference on
each visit and consistently encourage weight
maintenance/reduction through an appropriate balance of
physical activity, caloric intake, and formal behavioral
programs when indicated to maintain/achieve a BMI
between 18.5 and 24.9 kg/m2.
I (B) Modified recommendation
(changed text)
Start weight management and physical
activity as appropriate. Desirable BMI range
is 18.5 to 24.9 kg/m2.
2. The initial goal of weight-loss therapy should be to reduce
body weight by approximately 10% from baseline. With
success, further weight loss can be attempted if indicated
through further assessment.
I (B) Modified recommendation
(changed text)
If waist circumference is 35 inches or
greater in women or 40 inches or greater in
men, initiate lifestyle changes and treatment
strategies for metabolic syndrome.
3. If waist circumference (measured horizontally at the iliac
crest) is 35 inches (89 cm) or greater in women and 40
inches (102 cm) or greater in men, it is useful to initiate
lifestyle changes and consider treatment strategies for
metabolic syndrome as indicated.
I (B) Modified recommendation
(changed text)
Diabetes Management
Goal: HbA1c less than 7%
Appropriate glucose-lowering therapy to
achieve near-normal fasting plasma glucose,
as indicated by HbA1c.
1. It is recommended to initiate lifestyle and
pharmacotherapy to achieve near-normal HbA1c.
I (B) Modified recommendation
(changed text)
Treatment of other risk factors (e.g.,
physical activity, weight management, blood
pressure, and cholesterol management).
2. Beginning vigorous modification of other risk factors (e.g.,
physical activity, weight management, blood pressure
control, and cholesterol management as recommended
above) is beneficial.
I (B) Modified recommendation
(changed text)
3. Coordination of diabetic care with the patient’s primary
care physician or endocrinologist is beneficial.
I (C) New recommendation
Antiplatelet Agents/Anticoagulants: Aspirin
For all post-PCI stented patients, aspirin 325
mg daily should be given for at least 1
month after BMS implantation, 3 months
after sirolimus stent implantation, and 6
months after paclitaxel stent implantation,
after which daily long-term aspirin  (75
mg to 162 mg per day) should be continued
indefinitely in all patients if not
contraindicated.
1. For all post-PCI stented patients without allergy or
increased risk of bleeding, aspirin 162 mg to 325 mg
daily should be given for at least 1 month after BMS
implantation, 3 months after sirolimus-eluting stent
implantation, and 6 months after paclitaxel-eluting
stent implantation, after which long-term aspirin use
should be continued indefinitely at a dose of 75 mg to
162 mg daily.
I (B) Modified recommendation
(changed text)
2. In patients for whom the physician is concerned
about risk of bleeding, lower-dose 75 mg to 162 mg
of aspirin is reasonable during the initial period after
stent implantation.
IIa (C) New recommendation
Antiplatelet Agents/Anticoagulants: Clopidogrel
For post-PCI stented patients, clopidogrel 75
mg per day should be given for at least 1
month after BMS implantation, 3 months
after sirolimus stent implantation, and 6
months after paclitaxel stent implantation,
after which clopidogrel should ideally be
continued for up to 12 months in all stented
patients who are not at high risk of
bleeding.
1. For all post-PCI patients who receive a DES, clopidogrel
75 mg daily should be given for at least 12 months if
patients are not at high risk of bleeding. For post-PCI
patients receiving a BMS, clopidogrel should be given
for a minimum of 1 month and ideally up to 12 months
(unless the patient is at increased risk of bleeding; then
it should be given for a minimum of 2 weeks).
I (B) Modified recommendation
(changed text)
2. For all post-PCI non-stented STEMI patients, treatment
with clopidogrel should continue for at least 14 days.
I (B) New recommendation
3. Long-term maintenance therapy (e.g., 1 year) with
clopidogrel (75 mg per day orally) is reasonable in
STEMI and non-STEMI patients who undergo PCI
without reperfusion therapy.
IIa (C) New recommendation
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 Table 17. Continued
2005 PCI Recommendations 2007 PCI Recommendations 2007 COR and LOE Comments
Antiplatelet Agents/Anticoagulants: Warfarin
Manage warfarin to an INR of 2.5 to 3.5 for
post-MI patients when clinically indicated or
for those not able to take aspirin or
clopidogrel.
1. Managing warfarin to an INR equal to 2.0 to 3.0 for
paroxysmal or chronic atrial fibrillation or flutter is
recommended, and in post-MI patients when clinically
indicated (e.g., atrial fibrillation, left ventricular thrombus).
I (A) Modified recommendation
(changed text)
2. Use of warfarin in conjunction with aspirin and/or
clopidogrel is associated with an increased risk of
bleeding and should be monitored closely.
I (B) New Recommendation
3. In patients requiring warfarin, clopidogrel, and aspirin
therapy after PCI, an INR of 2.0 to 2.5 is
recommended with low dose aspirin (75 mg to 81 mg)
and a 75-mg dose of clopidogrel.
I (C) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: ACE Inhibitors
Consider use of ACE inhibitors for all CHD
patients indefinitely; start early after MI in
stable high-risk patients (anterior MI,
previous MI, Killip class greater than or
equal to II [S3 gallop, rales, radiographic
HF]).
1. ACE inhibitors should be started and continued indefinitely
in all patients with LVEF less than or equal to 40% and
for those with hypertension, diabetes, or chronic kidney
disease, unless contraindicated.
I (A) Modified recommendation
(changed text)
Use as needed to manage blood pressure or
consider for long-term therapy in all other
patients.
2. ACE inhibitors should be started and continued indefinitely
in patients who are not lower risk (lower risk defined as
those with normal LVEF in whom cardiovascular risk
factors are well controlled and revascularization has been
performed), unless contraindicated.
I (B) Modified recommendation
(changed text)
Continue indefinitely for all patients with LV
dysfunction (ejection fraction less than or
equal to 0.40) or symptoms of heart
failure.
3. Among lower risk patients (i.e., those with normal LVEF in
whom cardiovascular risk factors are well controlled and
revascularization has been performed) use of ACE
inhibitors is reasonable.
IIa (B) Modified recommendation
(changed text)
Renin-Angiotensin-Aldosterone System Blockers: Angiotensin Receptor Blockers
Use angiotensin receptor blockers in post-
STEMI patients who are intolerant of ACE
inhibitors and who have either clinical or
radiological signs of heart failure or LVEF
less than 0.40.
1. Use of angiotensin receptor blockers is recommended in
patients who are intolerant of ACE inhibitors and have HF
or have had an MI with LVEF less than or equal to 40%.
I (A) Modified recommendation
(changed text)
2. Angiotensin receptor blockers are useful in other
patients who are ACE-inhibitor intolerant and have
hypertension.
I (B) New recommendation
3. Considering use in combination with ACE inhibitors in
systolic dysfunction HF may be reasonable.
IIb (B) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: Aldosterone Blockade
Aldosterone blockade in post-STEMI patients
without significant renal dysfunction¶¶ or
hyperkalemia*** who are already
receiving therapeutic doses of an ACE
inhibitor, have an LVEF less than or equal
to 0.40, and have either diabetes or heart
failure.
1. Use of aldosterone blockade in post-MI patients without
significant renal dysfunction¶¶ or hyperkalemia*** is
recommended in patients who are already receiving
therapeutic doses of an ACE inhibitor and beta blocker,
have an LVEF of less than or equal to 40%, and have
either diabetes or HF.
I (A) Modified recommendation
(changed text)
nd STEM
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In the article by King et al, “2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update
for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines” that appeared in the January 15,
2008, issue of the journal, folio information for Circulation was incomplete in the footnote. The
complete citation is Circulation. 2008;117:261–295. The current online version of the article has
been corrected.
The publisher regrets this error.
DOI: 10.1161/CIRCULATIONAHA.107.188911
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